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ABSTRACT 
Transcriptional programs regulating myogenesis are multi-layered, requiring 
carefully orchestrated temporal activation of a wide range of myogenic transcription factors 
for proper muscle formation. The MEF2 transcription factor family is required for muscle 
differentiation, however the roles of individual mammalian MEF2 isoforms, MEF2A, -B, 
-C, and –D, in this process has not been thoroughly investigated. Acute knockdown of 
individual MEF2 isoforms in skeletal myoblasts revealed that MEF2A is required for 
myogenesis in vitro, whereas MEF2B, -C, and –D are dispensable for this process. 
Microarray analysis performed on myotubes depleted of each MEF2 isoform revealed that 
MEF2 factors regulate distinct gene programs in skeletal muscle. Moreover, computational 
analysis of the upstream regulatory regions of MEF2 isoform-dependent genes uncovered 
a distinct complement of transcription factor binding sites suggesting potential co-factor 
interactions in muscle gene regulation. Whereas all four MEF2 family members are 
 vii 
 
expressed in adult skeletal muscle, MEF2A and MEF2D are the major isoforms expressed 
in the post-natal heart. Previous studies in cardiomyocytes have demonstrated that MEF2A 
regulates genes encoding proteins localized to the costamere, an essential macromolecular 
complex required for proper muscle contraction. By contrast, genome-wide expression 
analysis suggests a role for MEF2D in cardiomyocyte cell cycle regulation. MEF2D- 
deficient cardiomyocytes up-regulate a subset of positive cell cycle regulators and display 
activation of the PI3K/AKT signaling pathway. Furthermore, MEF2D-depleted 
cardiomyocytes have increased levels of cytoplasmic FOXO3a, a cell cycle inhibitor and 
direct AKT target. Along these lines, MEF2D-depleted cardiomyocytes have decreased 
levels of the PI3K/AKT repressor PTEN. Analysis of the Pten promoter revealed a highly 
conserved MEF2 site, which is required for activation of this promoter by MEF2D. Taken 
together, these findings demonstrate that MEF2D modulates PI3K/AKT activation through 
transcriptional regulation of the tumor suppressor PTEN. In the absence of MEF2D, 
aberrant activation of the cell cycle ultimately results in cardiomyocyte cell death. These 
results demonstrate that MEF2 family members regulate distinct gene programs required 
for proper skeletal and cardiac muscle function.  
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CHAPTER 1: Introduction 
1.1 Introduction 
 This thesis focuses on the role of MEF2 transcription factors in mammalian striated 
muscle. MEF2 is comprised of four family members MEF2A, -B, -C, and –D which share 
high conservation but have distinct roles in muscle development and disease. This work is 
divided into two parts. Chapter three delves into the requirement of each MEF2 factor in 
skeletal muscle differentiation and the gene programs each factor distinctly regulates. 
Chapters four and five focus on the roles of MEF2D in cardiomyocyte proliferation and 
cell death. Many muscle diseases, including cardiovascular disease, are a result of dying 
muscle which is unable to regenerate efficiently. Dissecting the transcriptional networks 
required for proper muscle formation and growth will help to advance our understanding 
of signaling cues necessary for proper muscle regeneration.  
1.2. Myocyte Enhancer Factor-2 Transcription Factors 
1.2.1 Identification and structure of MEF2 
Myocyte Enhancer Factor-2 (MEF2) was originally identified as a myocyte-
specific nuclear factor that bound an A/T rich sequence within the muscle creatine kinase 
(mck) promoter. This newly identified factor was expressed before MCK in differentiated 
myotubes, designating MEF2 as an early molecular marker of the muscle differentiation 
program (Gossett et al., 1989). Ultimately, four mammalian MEF2 family members were 
discovered and named MEF2A, -B, -C, and –D (Breitbart et al., 1993; Martin et al., 1994; 
McDermott et al., 1993; Pollock and Treisman, 1991; Yu et al., 1992). In contrast to 
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mammals which have four Mef2 genes, Drosophila and C. elegans possess just one mef2 
gene, encoding D-MEF2 and CeMEF2, respectively (Dichoso et al., 2000; Lilly et al., 
1994). Saccharomyces cerevisiae (budding yeast) and Xenopus each have two mef2 genes, 
designated rlm1 and smp1 in yeast, and Xmef2a and Xmef2d in Xenopus (Dodou and 
Treisman, 1997; Wong et al., 1994).  
MEF2 factors have highly conserved N-terminal regions, with little to no homology 
in their C-terminal halves (Fig.1.1). All MEF2 proteins belong to the MADS-box family 
of transcription factors, characterized by a 57-aa motif called the MADS box. The MADS-
box family is named after the first four members to be identified (MCM1, Agamous, 
Deficiens, and SRF) (Shore and Sharrocks, 1995). Adjacent to the MADS box is another 
conserved 29-aa region, the MEF2 domain. Together, the MADS box and MEF2 domain 
mediate DNA binding and dimerization, and are necessary for protein-protein interactions 
between MEF2 and its co-activators (Molkentin et al., 1995; Pollock and Treisman, 1991). 
MEF2 factors share approximately 50% aa identity overall, with 95% similarity among the 
MADS and MEF2 domains. MEF2 proteins are capable of forming homo- and 
heterodimers, but cannot form heterodimers with other MADS box family members. The 
highly divergent C-terminal region contains the transactivation domain and is subject to 
complex alternative splicing (Figure 1.2), with some muscle- and neuronal-specific 
isoforms being produced (Breitbart et al., 1993; Martin et al., 1994; Pollock and Treisman, 
1991; Yu et al., 1992). 
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1.2.2     MEF2 expression and transcriptional activity 
1.2.2.1     MEF2 transcript expression  
MEF2 transcripts are expressed in overlapping but distinct patterns throughout 
development (Fig.1.3). Mef2b and Mef2c are turned on first, and are detected at embryonic 
day 7.5 (E7.5) in the cardiac mesoderm of mouse embryos (Edmondson et al., 1994; 
Molkentin et al., 1996). Mef2a and Mef2d are detectable  in the myocardium by E8.5, and 
continue to be expressed in the heart throughout development and into adulthood 
(Edmondson et al., 1994). Mef2b and -c expression begins to decline around E10.5 and 
transcripts are undetectable by in situ hybridization post E13.5. MEF2 transcripts are 
detected in a similar temporal expression pattern in skeletal muscle (Fig.1.3), with Mef2c 
mRNA being detected at E8.5-9.0 (Edmondson et al., 1994). Mef2b expression follows half 
a day later at E9.0 (Molkentin et al., 1996). Mef2a and –d are detectable beginning at E9.5, 
and continue to be expressed throughout skeletal muscle  development and into adulthood 
(Edmondson et al., 1994). Whereas in the heart Mef2b and –c levels trail off by E13.5, they 
continue to be expressed in skeletal muscle throughout development and after birth 
(Edmondson et al., 1994; Molkentin et al., 1996).  Several skeletal muscle lineage markers 
and structural genes are expressed prior to Mef2 (Fig.1.4), suggesting that some of these 
markers initiate Mef2 expression in skeletal muscle during development. Interestingly, 
several studies have found that MEF2A, -B, and D are expressed in  myoblasts prior to the 
onset of myogenin expression, suggesting that MEF2 activates this gene (Breitbart et al., 
1993).   
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1.2.2.2     MEF2 transcriptional activity 
Sensor mice harboring the lacZ reporter gene are a commonly used tool for 
measuring transcriptional activity of proteins. MEF2 sensor mice were generated by 
placing lacZ gene expression under the control of three tandem copies of the desmin MEF2 
site (des-MEF2-lacZ) (Naya et al., 1999). Desmin is a muscle-specific structural protein 
found in the contractile units within striated and smooth muscle. Therefore, des-MEF2-
lacZ mice are useful in determining MEF2 protein activity in all muscle types. lacZ 
expression is first detected at E7.5 in cardiac muscle cell precursors (Naya et al., 1999), 
coinciding with the onset of Mef2b and Mef2c expression in the developing embryo 
(Edmondson et al., 1994; Molkentin et al., 1996). Interestingly, initial MEF2 
transcriptional activity is localized to cells near the cardiac crescent, but is detected in the 
atria and ventricles by E11.5. In agreement with in situ hybridization studies looking at 
Mef2b and –c expression in the heart, MEF2 activity begins to decline after E14.5, 
suggesting that MEF2B and MEF2C are responsible for the majority of the transcriptional 
activity in the developing heart.   
Des-MEF2-lacZ mice show expression in the somites, which give rise to the 
vertebrae and skeletal muscle, starting at E9.0-9.5 (Naya et al., 1999). MEF2 
transcriptional activity continues throughout skeletal muscle development and persists in 
neonatal and adult sensor mice. In skeletal muscle, MEF2 activity coincides with the Mef2 
transcript developmental expression timeline previously described in other studies 
(Edmondson et al., 1994). lacZ expression is also detected in the developing brain and 
nervous system in a pattern consistent with mRNA expression (Lyons et al., 1995). In 
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contrast to the ubiquitous expression of most Mef2 transcripts (Breitbart et al., 1993; Martin 
et al., 1994; Ornatsky and McDermott, 1996; Yu et al., 1992), MEF2 activity, as measured 
by this reporter, appears restricted to developing muscle and the brain, and is not detected 
in the adult heart or other adult tissues (Naya et al., 1999). While MEF2 activity is high in 
muscle and brain, several reports demonstrate MEF2 activity in a wide range of tissue and 
cell types. 
1.2.3     MEF2 Regulation 
1.2.3.1     Transcriptional control 
MEF2 factors regulate a diverse array of developmental programs, including cell 
division, differentiation, and cell death (McKinsey et al., 2002; Potthoff and Olson, 2007). 
A cell’s decision to divide or die is highly regulated and dependent on mutually exclusive 
signaling cues. Accordingly, MEF2 factors are subject to complex patterns of regulation 
due to their roles as central regulators in opposing pathways. MEF2 factors are regulated 
at the transcriptional, translational, and post-translational levels through interactions with 
a variety of activators and repressors (Black and Olson, 1998; McKinsey et al., 2002).  
Mammalian Mef2 genes have long 5’ untranslated regions (UTR) that are subject to 
complex patterns of alternative splicing, making it difficult to investigate transcriptional 
control of these genes. Thus far, the enhancers of Mef2 have primarily been characterized 
in Drosophila. At least twelve independent enhancers exist within the 12 kbp upstream of 
D-mef2, and have been shown to direct transcription of D-mef2 in a temporospatial pattern 
during development (Black and Olson, 1998). Regulatory regions upstream of mammalian 
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Mef2a and Mef2c have been partially characterized (Ramachandran et al., 2008b; Wang et 
al., 2001). The 5’UTR regions of mammalian Mef2 genes contain regulatory regions that 
bind myogenic bHLH and MEF2 proteins to regulate transcription (Ramachandran et al., 
2008b; Wang et al., 2001). Additionally, Mef2a is a direct transcriptional target of nuclear 
respiratory factor 1 (NRF1) (Ramachandran et al., 2008a). While no regulatory regions 
have been identified yet for Mef2b or –d, these findings support that regulation of MEF2 
expression occurs at the transcriptional level. Thus, transcriptional regulation can account 
for the overlapping but distinct temporal expression patterns of mammalian MEF2 
transcripts throughout development.   
1.2.3.2     Translational control 
MEF2 transcripts are expressed ubiquitously, with the exception of Mef2c which is 
restricted to skeletal muscle, brain and spleen (Martin et al., 1994; McDermott et al., 1993; 
Pollock and Treisman, 1991; Yu et al., 1992). However, translational control of MEF2 
transcripts highly restricts protein expression to striated muscle and the brain (Breitbart et 
al., 1993; McDermott et al., 1993; Yu et al., 1992). Several studies have demonstrated that 
microRNAs regulate expression of transcription factors important for skeletal and cardiac 
muscle development (Small and Olson, 2011). Mef2a contains an evolutionarily conserved 
sequence within its 3’UTR that inhibits MEF2A protein expression in non-muscle cells 
(Black et al., 1997). miR-155 inhibits skeletal myoblast differentiation by binding a 
sequence with the 3’UTR of MEF2A and preventing translation. In the heart, Mef2a 
translation is negatively regulated by miR-1 to attenuate cardiomyocyte hypertrophy (Ikeda 
et al., 2009). Given the high evolutionary conservation of MEF2 factors across species, it 
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is not surprising that this mechanism of translational control is conserved in Drosophila 
where miR-92b negatively regulates expression of dmef2 by binding the 3’UTR (Chen et 
al., 2012).     
1.2.3.3     Post-translational control: Protein partners and post-translational 
modifications  
Histone deacetylases (HDACs) inhibit MEF2 transcriptional activity by forming 
repressive complexes at MEF2-dependent gene regulatory regions. Class II HDACs 4, 5, 
7 and 9 associate with DNA-bound MEF2 proteins and deacetylate nucleosomal histones 
to repress gene expression. An increase of intracellular calcium levels results in the 
phosphorylation of HDACs, creating a docking site for 14-3-3 which disrupts HDAC-
MEF2 interactions and masks the HDAC nuclear localization signal (NLS). HDAC is 
subsequently shuttled out of the nucleus and MEF2-dependent gene transcription can 
occur. 14-3-3 can also directly interact with the MADS/MEF2 domains of MEF2D to 
stimulate its activity (McKinsey et al., 2002). It is important to note that Class II HDACs 
are predominantly expressed in the heart, brain, and skeletal muscle, indicating that post-
translational control of MEF2 activity occurs through other mechanisms in non-muscle 
cells.  
The p38 and ERK/MAPK pathways directly phosphorylate MEF2, leading to an 
increase in MEF2 transcriptional activity to promote cell growth and differentiation. p38 
activates MEF2D by direct phosphorylation of the MADS/MEF2 domain. Activated 
MEF2D then interacts with MyoD to activate expression of late myogenic markers such as 
α-MHC and desmin. This is in sharp contrast to MEF2’s pro-apoptotic function in 
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thymocytes where MEF2D interacts with NFAT to promote cytochrome c-mediated 
apoptosis by activating transcription of the nurr77 gene (McKinsey et al., 2002). MEF2 
proteins interact with a variety of transcription factors to regulate diverse developmental 
programs (Black and Olson, 1998; Potthoff and Olson, 2007). In this way, MEF2 binding 
partners serve to modulate MEF2 activity within the context of the cell.  
1.2.4 Loss of function analysis of MEF2  
1.2.4.1 Invertebrate MEF2 loss of function 
D-mef2 null Drosophila do not develop differentiated muscle and die during 
embryogenesis (Bour et al., 1995; Lilly et al., 1994). In contrast, Ce-mef2 is not required 
for muscle development in C. elegans and mutants have no strong visible phenotype or 
overt defects throughout myogenesis. However, CeMef2 mutant animals are short and 
dumpy as adults, implicating MEF2 in pathways other than muscle development in C. 
elegans (Dichoso et al., 2000).  MEF2 is completely dispensable in C. elegans myogenesis 
and development, but is absolutely required for Drosophila muscle differentiation. Thus, 
while the MEF2 family of transcription factors is highly conserved among species, there 
appears to be variability in protein function and requirement for proper muscle 
development and differentiation between species.  
1.2.4.2 Vertebrate MEF2 loss of function  
Zebrafish mef2c/ mef2d knockdown mutants develop normally during embryogenesis, 
but fail to form thick filaments and have severe skeletal muscle defects after birth. These 
abnormalities are due to decreased expression of the thick filament components myosin 
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heavy chain, myosin light chain, and myosin binding protein C which are necessary for 
muscle function and sarcomere assembly (Hinits and Hughes, 2007).  
In Xenopus, MEF2D is required for proper expression of muscle identity genes and 
dermomyotome formation (Della Gaspera et al., 2012). In this model, MEF2D functions 
in combination with FGF to activate mesoderm gene expression and patterning. As a result, 
MEF2D depletion causes delayed gastrulation and failure of embryo elongation 
(Kolpakova et al., 2013).  
MEF2 factors have indistinguishable binding specificities in vitro and display similar 
transactivation potentials by reporter assays (Breitbart et al., 1993; Lilly et al., 1994; 
McDermott et al., 1993; Pollock and Treisman, 1991; Yu et al., 1992). The function of 
MEF2 family members is so highly conserved that D-MEF2 is capable of binding to and 
activating mammalian genes (Lilly et al., 1994; Nguyen et al., 1994). In vitro studies 
suggest that MEF2 factors act redundantly, however animal model knockouts for each of 
the four mammalian Mef2 genes reveal that these four factors regulate unique subsets of 
genes and biological processes in vertebrates.   
MEF2A knockout mice suffer from perinatal lethality and sudden death due to severe 
cardiac cytoarchitectural defects and mitochondrial deficiency in the heart. Microarray 
analyses using cardiac RNA show that mitochondrial, structural, and stress-responsive 
genes are significantly dysregulated in MEF2A knockouts and resemble a gene program 
characteristic of cardiac failure (Naya et al., 2002). Interestingly, MEF2A knockout mice 
show no skeletal muscle defects at the histological level (Naya et al., 2002). However, 
skeletal muscle regeneration is impaired in adult mice in the absence of MEF2A due to 
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aberrant Wnt signaling (Snyder et al., 2013). In contrast, differentiation is not impaired 
when MEF2A is deleted specifically in adult satellite cells in the context of muscle injury, 
but is perturbed when MEF2A, -C, and -D are deleted simultaneously in these cells (Liu et 
al., 2014). Studies performed in vitro also reveal important roles for MEF2A in muscle 
differentiation. A dominant-negative form of MEF2A lacking a transcriptional activation 
domain inhibits myotube formation and expression of the muscle regulatory genes 
myogenin, MHC, and MEF2A in L6E9 and C2C12 myoblasts. Moreover, expression of 
dominant-negative MEF2A in C3H10T1/2 fibroblasts impairs MyoD mediated myogenic 
conversion, suggesting that MEF2A is required for muscle specific gene expression and 
myogenesis in this context (Ornatsky et al., 1997).   
MEF2B null mice are viable with no obvious phenotype (Black and Olson, 1998).  
MEF2C knockout mice die prenatally due to a heart looping morphogenesis defect 
which results in failure of formation of the future right ventricle (Lin et al., 1997). In 
addition, structural genes such as α-MHC and cardiac α-actin, which are involved in 
contraction, fail to express thereby impairing circulation and further compounding the 
morphogenic heart defects observed (Lin et al., 1997). Furthermore, MEF2C null embryos 
fail to form vascular systems and exhibit disorganized assembly of endothelial cells (Lin 
et al., 1998). A conditional skeletal muscle MEF2C knockout mouse revealed that MEF2C 
null skeletal muscle rapidly degenerates perinatally, has impaired function, and sarcomere 
integrity is compromised (Potthoff et al., 2007).  The strong cardiac phenotype observed 
in MEF2C null mice is supported by overexpression of MEF2C in the p19 cardiac cell line, 
where MEF2C is sufficient to induce cardiomyogenesis. In this context, MEF2C 
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overexpression upregulates expression of Bmp4, Nkx2-5, Gata4, cardiac α-actin, and MHC 
which is sufficient to direct the early stages of cardiomyocyte differentiation (Skerjanc et 
al., 1998). Taken together, these results indicate that MEF2C is required for proper 
formation of the heart and vascular systems, and necessary for proper sarcomere assembly 
and myofiber maintenance perinatally. 
MEF2D null mice are viable, and have no histological abnormalities in a range of tissue 
types, including skeletal and cardiac muscle (Kim et al., 2008). However, MEF2D mutants 
exhibit a blunted pathological response to cardiac pressure overload, including resistance 
to cardiac remodeling and fibrosis, when compared to wild-type mice (Kim et al., 2008). 
Overexpression of MEF2D resulted in fibrosis and hypertrophy (Kim et al., 2008), both of 
which are pathological symptoms of injury to the heart. Moreover, MEF2D overexpression 
results in a distinct cardiac phenotype since overexpression of MEF2A or MEF2C results 
in dilated cardiomyopathy with little or no hypertrophy (Xu et al., 2006), suggesting that 
MEF2D targets a unique set of cardiac genes.  
1.2.5 MEF2 and myogenesis 
MEF2 dimers bind the consensus sequence CTA(A/T)4TAG found in the promoters 
and enhancers of most muscle-specific genes, but are unable to activate the skeletal muscle 
differentiation program on their own (Molkentin et al., 1995). Instead, MEF2 proteins 
cooperate with myogenic basic helix-loop-helix (bHLH) proteins to potentiate skeletal 
muscle differentiation. The MyoD family of myogenic bHLH transcription factors, MyoD, 
Myogenin, Myf5, and MRF4, control the specification and differentiation of skeletal 
muscle cells. Ectopic expression of any one of these four factors is sufficient to initiate the 
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muscle differentiation program in muscle and non-muscle cells, and Myogenic bHLH 
proteins must heterodimerize with E proteins and bind to the consensus DNA sequence 
CANNTG (E-box) in the promoters of muscle specific genes in order to initiate the 
myogenic program (Black and Olson, 1998). E-boxes and MADS/MEF2 domains are 
frequently positioned next to each other in muscle gene promoters, thus allowing for 
myogenic bHLH factors and MEF2 proteins to bind simultaneously (Fickett, 1996). In this 
way, bHLH and MEF2 transcription factors act synergistically to promote the skeletal 
muscle differentiation program (Molkentin et al., 1995). Interestingly, MEF2 expression is 
detected shortly after induction of Myf5 and MyoD expression (Fig.1.3).  
1.2.6 MEF2 in proliferation and cell death 
MEF2 proteins are central regulators of diverse signaling pathways. There is substantial 
evidence implicating MEF2 transcription factors in cell proliferation, an uncontrolled 
pathway in cancer. Interestingly, MEF2 target genes are repressed in a wide range of soft 
tissue sarcomas. Ectopic MEF2 expression blunts proliferation in these tumors and returns 
cells to low proliferation levels (Di Giorgio et al., 2013), suggesting MEF2 behaves as a 
tumor suppressor in soft tissue sarcomas. In contrast, overexpression of MEF2D in 
hepatocellular carcinoma sustains tumorigenicity by promoting cell cycle progression (Ma 
et al., 2014).  
Several additional studies implicate MEF2 as a regulator of the cell cycle in healthy 
cells. Vascular myocytes display increased levels of MEF2A transcriptional activity when 
induced to proliferate with serum (Suzuki et al., 1995). Moreover, MEF2C mediates B-cell 
proliferation and survival by inducing expression of several cell cycle and pro-survival 
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genes, such as cyclin D2 and Bcl-xl, respectively (Wilker et al., 2008). Studies performed 
in fibroblasts demonstrate that MEF2C and –D are down-regulated when cells are 
stimulated to re-enter the cell cycle with serum, and upregulated as cells exit the cell cycle. 
The anti-proliferative role of MEF2 in these cells is mediated through transcriptional 
activation of the cell cycle repressor Cdkn1a, and MEF2D knockdown results in decreased 
CDKN1A/p21, and increased DNA synthesis and proliferation (Fig. 1.5) (Di Giorgio et al., 
2015). This cell cycle activation is maintained through a regulatory loop where 
CDK4/cyclin D1 phosphorylates and inactivates MEF2D, further promoting cell cycle 
progression (Di Giorgio et al., 2015). The role of MEF2 in proliferation and cell survival 
is a controversial area of study, and it is likely that the effects of MEF2 effects on the cell 
cycle are context-dependent and vary by cell type. 
In addition to studies investigating the role of MEF2 in cell cycle control and 
proliferation, MEF2 activity has been intensely examined in neuronal cell survival. MEF2 
factors have established roles as pro-survival factors in neurons (Mao et al., 1999). Several 
studies demonstrate that MEF2 depletion in neurons results in neuronal cell death 
(Gaudilliere et al., 2002; Kim et al., 2011; Salma and McDermott, 2012). This protective 
role is in sharp contrast to MEF2’s pro-apoptotic function in thymocytes where MEF2D 
interacts with NFAT to promote cytochrome c-mediated apoptosis (McKinsey et al., 2002). 
1.2.7    MEF2 in disease 
MEF2 dysregulation is associated with a variety of diseases in a broad range of 
tissue types. Loss of MEF2 activity can result in tumorigenicity or tumor suppression in a 
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context-dependent manner. MEF2 proteins are significantly depleted in soft tissue sarcoma 
samples, and restoration of MEF2 activity suppresses tumor growth (Di Giorgio et al., 
2013). The opposite effect is observed in T-cells, where increased levels of MEF2C and 
MEF2D maintain malignancy of lymphoblastic leukemia cells (Homminga et al., 2011; 
Lund et al., 2002; Prima and Hunger, 2007; Suzuki et al., 2002). The oncogenic potential 
of MEF2 depletion is not surprising, given that MEF2D promotes apoptosis in thymocyte 
selection (McKinsey et al., 2002).  
Neurodegenerative and muscular diseases are marked by high levels of cell death 
with an inability to replenish damaged cells. Many of the available therapies target 
pathways that promote cell survival and inhibit apoptosis. Transcription factors are central 
regulators of a broad range of cellular processes, and as such are appealing targets of gene 
therapies. MEF2 factors have been implicated in both neuroprotection and the pathology 
associated with heart disease. Patients suffering from Parkinson’s disease exhibit 
debilitating motor defects due to neuronal cell death. In neurons, up-regulation of MEF2D 
protects against apoptosis and ameliorates Parkinson’s disease motor defects in mice (Yao 
et al., 2012). Furthermore, there is substantial evidence that implicates MEF2 as a 
downstream effector in models of cardiac dysfunction (Kolodziejczyk et al., 1999; Passier 
et al., 2000).  
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1.3 Cardiomyocyte Cell Cycle Control  
1.3.1 PI3K/AKT pathway 
The phosphatidylinositol-3 kinase (PI3K)- AKT/protein kinase B (PKB) signaling 
pathway has a critical role in cell cycle progression and cell survival (Fig.1.6) (Cantley, 
2002; Liang and Slingerland, 2003; Oudit et al., 2004). Due to this pathway’s important 
roles in the cell its activity is tightly regulated and hyper-activation is associated with cell 
cycle deregulation in cancers (Nagoshi et al., 2005; Oudit et al., 2008; Steelman et al., 
2011). Acute AKT activation is cardioprotective in the injured adult heart, by its ability to 
promote cell survival and block cell death (Steelman et al., 2011). It is therefore not 
surprising that patients who suffer from cardiac disease display an increase in AKT 
activation. However, chronic activation of AKT is maladaptive and results in increased 
heart failure (Nagoshi et al., 2005).  
PI3K-AKT/PKB mediates its effects on cell cycle and cell death pathways through 
interactions with a variety of downstream targets. One well-established substrate of AKT 
is the Forkhead box O (FOXO) family of transcription factors comprised of FOXO1 
(FKHR), FOXO3a (FKHRL-1), and FOXO4 (AFX), which are known to regulate 
differentiation, metabolism, proliferation, and survival (Accili and Arden, 2004; Skurk et 
al., 2004). AKT promotes cell cycle progression and survival by phosphorylating FOXO, 
which results in FOXO inactivation by nuclear extrusion (Liang and Slingerland, 2003).  
PI3K-AKT/PKB interacts with pro-apoptotic proteins to regulate cell death and 
survival. One such substrate is Bcl-2 associated death promoter (BAD), which when 
phosphorylated by AKT is unable to inhibit the pro-survival factor Bcl2 (Steelman et al., 
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2011). Furthermore, AKT blocks cytochrome-C release from the mitochondria, an event 
which is known to activate the apoptotic caspase cascade (Steelman et al., 2011). 
PTEN is a membrane bound lipid phosphatase that functions to inhibit the PI3K-
AKT/PKB pathway by antagonizing PI3K activities in the heart (Crackower et al., 2002; 
Hamada et al., 2005; Oudit et al., 2004; Wishart and Dixon, 2002). Mutations in the PTEN 
gene are present in a large number of cancers (Liang and Slingerland, 2003), making this 
clinically relevant protein an important tumor suppressor. Interestingly, a mouse model of 
human hypertrophic cardiomyopathy revealed reduced PTEN expression, implicating 
PTEN in heart disease (Lutucuta et al., 2004). To better understand PTEN’s direct role in 
heart disease, a murine knockout model was generated. The loss of PTEN led to an increase 
in phosphorylation of AKT/PKB and glycogen synthase kinase-3β (GSK3β), resulting in a 
blunted response to pathological hypertrophy in response to stress (Oudit et al., 2008). 
These findings demonstrate that PTEN contributes to the progression of heart failure and 
the associated maladaptive cardiac remodeling. Curiously, the PTEN knockout phenotype 
closely mimics the MEF2D knockout mouse model which also displays resistance to 
cardiac remodeling in response to stress. Because of the similarity between the PTEN and 
MEF2D knockout models it is tempting to speculate that MEF2D and PTEN function in 
the same pathway to modulate cardiac remodeling. 
1.3.2 FOXO transcription factors 
The Forkhead box O (FOXO) family of transcription factors has been associated with 
regulation of proliferation, metabolism, and aging (Huang and Tindall, 2007). FOXO 
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family members negatively regulate cardiomyocyte proliferation, and promote neonatal 
cell cycle withdrawal by transcriptionally activating several cell cycle inhibitors (Evans-
Anderson et al., 2008). Murine knockout models reveal that FOXO transcriptional activity 
is necessary for the proper development of the heart. FOXO1 null mice die embryonically 
before initiation of cardiac morphogenesis (Hosaka et al., 2004), whereas FOXO3-
deficient mice develop normally but develop cardiac hypertrophy in adulthood (Ni et al., 
2006). Moreover, increased levels of FOXO1 are implicated in human heart failure 
(Hannenhalli et al., 2006). These striking cardiac abnormalities showcase the importance 
of FOXO transcription factors in proper cardiac development and function.  
 FOXO transcription factors are negatively regulated by AKT through 
phosphorylation and subsequent nuclear export (Huang and Tindall, 2007).  Cytoplasmic 
FOXO is unable to transcriptionally activate the genes encoding cell cycle inhibitors p21, 
p27, and p57, allowing cell cycle progression to occur (Fig. 1.7). Inhibition of FOXO 
activity results in increased levels of cardiomyocyte proliferation, whereas FOXO1 
overexpression is associated with decreased cardiomyocyte proliferation and increased 
levels of p21, p27, and p57 (Evans-Anderson et al., 2008). FOXO transcription factors 
coordinately regulate cell cycle withdrawal in neonatal cardiomyocytes a process which is 
necessary for completion of cardiac development and maturation into a properly 
functioning heart.  
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1.3.3 E2F transcription factors 
The E2F family of transcription factors regulates genes involved in cell cycle 
progression and cell death. The family is comprised of nine family members encoded by 
eight genes, and is subdivided into activating and repressive groups. E2F1, -2, and -3 
(E2F1-3) are activating E2Fs and promote cell cycle progression by transcriptionally 
activating positive cell cycle genes involved in the G1/S phase of the cell cycle (Fig.1.8) 
(Iaquinta and Lees, 2007). Among genes known to be activated by E2F1-3 are 
minichromosome maintenance complex component 4 (Mcm4), Mcm5, Mcm6, cell division 
cycle 6 (Cdc6), and cyclin E (Ccne) (Polager and Ginsberg, 2008).  Little is known about 
E2F3b, which results from an alternative splicing event of the E2F3 gene, however it is 
believed to be a transcriptional repressor. E2F4, -5, -6, -7, and -8 repress transcriptional 
activity and maintain the cell in a quiescent state by inhibiting genes necessary for cell 
cycle progression (Fig.1.8) (Iaquinta and Lees, 2007). One notable upstream regulator of 
E2F is retinoblastoma 1 (pRb), which inhibits E2F1-3 to block cellular proliferation 
(Iaquinta and Lees, 2007). When the cell receives a signal to divide, cyclin D promotes 
phosphorylation of pRb to inactivate it, releasing E2F1-3 inhibition and allowing 
transcription of genes involved in DNA replication and cell cycle progression (Polager and 
Ginsberg, 2008).   
Paradoxically, E2F1-3 can promote cell cycle progression and induce apoptosis. It 
is unclear how E2F1-3 decide under which circumstances to promote proliferation versus 
cell death. One likely hypothesis is that these opposing cell fates arise from post-
translational modifications of E2F proteins, as well as associations with a wide range of 
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E2F interacting proteins (Polager and Ginsberg, 2008). While E2F2 and 3 are able to 
mediate apoptosis, cell death is always an E2F1 dependent process making E2F1 
particularly important in this context (Iaquinta and Lees, 2007). E2F1-3 facilitate cell death 
via activation of a variety of pro-apoptotic genes and repression of pro-survival genes 
(Polager and Ginsberg, 2008).  
1.4 Statement of Thesis Rationale 
The MEF2 family of transcription factors are central regulators of cellular pathways 
important for cellular proliferation, differentiation, and homeostasis. The four mammalian 
MEF2 family members, MEF2A, -B, -C, and –D share high aa identity, and loss of function 
models for individual MEF2 proteins reveal unique muscular abnormalities. The primary 
goal of the research presented in this thesis is to further dissect the role of each mammalian 
MEF2 factor in striated muscle. Using an siRNA approach followed by microarray 
analysis, we have performed global gene expression profiling examining MEF2 sensitive 
gene sets in skeletal muscle and cardiomyocytes.  A better understanding of how MEF2 
members coordinately regulate gene programs in striated muscle may provide new areas 
of focus for developing therapeutic interventions to treat muscle disease.  
 
 
 
 
  
20 
 
 
      
    
 
 
FIGURE 1.1. Myocyte Enhancer Factor 2 family of transcription factors are 
evolutionarily conserved. MEF2 is an evolutionarily conserved family of transcription 
factors. Proteins share an overall 50% aa identity, and approximately 95% similarity within 
the MADS box and MEF2 domains. Taken from (Potthoff and Olson, 2007).  
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FIGURE 1.2. MEF2 proteins are subject to complex alternatively splicing. Schematic 
diagram of the mammalian MEF2 genes. The MADS box and MEF2 domains mediate 
DNA binding and dimerization.  The carboxyl terminal contains the transactivation domain 
and is alternatively spliced. Alternative exons are indicated along with the aa length of the 
longer form of each protein. Taken from (Black and Olson, 1998).   
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FIGURE 1.3. Temporal expression of Mef2 in striated muscle development.  Transcript 
expression patterns were detected in mouse embryos via in situ hybridization.  Mef2 is 
detected as early as embryonic day 7.5 (E7.5) in the heart, and E8.5 in skeletal muscle. 
Arrows indicate continued expression, whereas vertical lines indicate mRNA levels are 
undetectable. Adapted from (Edmondson et al., 1994).  
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FIGURE 1.4. MEF2 and MyoD family transcription factors are expressed throughout 
myogenesis. Muscle precursor cells rapidly divide, differentiate, and mature into 
myofibers. MEF2 expression is detected early on in the muscle lineage prior to the onset 
of differentiation in satellite cells. Typical cell identity and differentiation markers are 
shown at approximate time of expression. MHC: Myosin heavy Chain; skm actin: skeletal 
muscle actin. Adapted from (Zammit et al., 2006).  
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FIGURE 1.5. Model for MEF2 mediated cell cycle repression in fibroblasts. Under 
baseline conditions, MEF2C and –D maintain cells in a quiescent state by transcriptionally 
activating the cell cycle repressor CDKN1A/p21. Fibroblasts induced to proliferate with 
serum have decreased levels of MEF2C and –D activity. Upon cell cycle activation, 
CDK4/Cyclin D1 phosphorylate MEF2 to promote its degradation. Taken from (Di Giorgio 
et al., 2015).  
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 FIGURE 1.6. PI3K/AKT signaling pathway. The PI3K/AKT/PKB signaling pathway 
regulates a wide range of cellular processes, including the cell cycle. AKT activation results 
in Cyclin D1 activation and cell cycle progression. PTEN negatively regulates AKT by 
antagonizing PI3K activation of this pathway. Illustration reproduced courtesy of Cell 
Signaling Technology, Inc. (www.cellsignal.com). 
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FIGURE 1.7. FOXO transcription factors inhibit proliferation in the heart. Cardiac 
myocytes are maintained withdrawn from the cell cycle by FOXO inhibitory actions. 
FOXO transcription factors induce expression of CIP/KIP cell cycle inhibitors p21, p27, 
and p57. PI3K/AKT pathway is activated in response to growth signals, resulting in FOXO 
phosphorylation and nuclear exclusion. Cytoplasmic FOXO is no longer able to inhibit cell 
cycle progression and cells are able to proliferate. Taken from (Evans-Anderson et al., 
2008).  
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FIGURE 1.8. E2F transcription factors regulate cell cycle gene expression.  E2F1, -2, 
and -3 are activating E2Fs and promote cell cycle progression by transcriptionally 
activating positive cell cycle genes involved in the G1/S phase of the cell cycle. E2F4 and 
-5 antagonize the actions of E2F1-3 by repressing transcriptional activity and maintaining 
the cell in a quiescent state. E2F1-3 are maintained inactive by Retinoblastoma (pRb). 
Cyclin D promotes phosphorylation of Rb to inactivate it in response to growth cues. 
Subsequently, E2F1-3 inhibition is realized and transcription of genes involved in DNA 
replication and cell cycle progression occurs. Taken from (Polager and Ginsberg, 2008).   
 
29 
 
 
Chapter 2: Materials and Methods 
2.1 Recombinant DNA Techniques  
2.1.1 Transformation of DH5α Cells 
Frozen aliquots of chemically competent DH5α cells were thawed on ice. Approximately 
20 ng – 100 ng of plasmid DNA or 2 µL of a ligation reaction was added to 20 µL DH5α 
cells and incubated on ice for 10 min. Cells were heat shocked at 42ºC for 30 sec, then 
placed back on ice for two min. 250 µL pre-warmed LB was added to the reaction and cells 
were allowed to recover for one hour shaking at 37ºC. Cells were plated on LB plates 
containing the appropriate antibiotic (ampicllin 100 µg/mL, kanamycin 50 µg/mL), sealed 
with parafilm, and incubated upside-down for 16-18 h at 37ºC. Isolated colonies were 
picked and inoculated in 3 mL LB containing the appropriate antibiotic. Cultures were 
grown with shaking for 16-18 h at 37ºC. The liquid 3 mL cultures were then used for 
inoculation of a 100 mL culture, or were processed for plasmid purification.  
2.1.2        DNA Preparation 
2.1.2.1     Mini Prep  
For small-scale DNA preparations, 1 mL of a 3 mL culture was transferred to a 1.7 mL 
microcentrifuge tube and centrifuged for 30 sec at 14,000 rpm. The supernatant was 
aspirated, and the bacterial cell pellet was resuspended in 100 µL resuspension buffer (50 
mM glucose, 10 mM EDTA pH 8.0, 25 mM Tris pH 8.0) by gentle vortexing. To lyse the 
cells, 200 µL lysis solution (200mM NaOH, 1% SDS) was added and tubes were mixed by 
inversion five times. Reactions were incubated at room temperature for 4 min. The lysis 
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reaction was stopped by adding 150 µL neutralization buffer (3M potassium acetate, 11.5% 
acetic acid) and mixed by inversion five times. Plasmid DNA was purified by 
phenol/chloroform extraction. Dried pellets were resuspended in 20 µL sterile water 
containing 100 µg/mL RNase and incubated at 37ºC for 15 min. Samples were stored at -
20ºC.   
2.1.2.2     Midi Prep 
For medium-scale DNA preparations, NuleoBond® PC (Clontech) columns were used. 
Preparations were made according to manufacturer’s instructions. 
2.1.2.4    Phenol/Chloroform Extraction 
An equal volume of 1:1 phenol/chloroform was added to sample being purified. Samples 
were vortexed and centrifuged at 14,000 rpm for one min. The aqueous (upper) phase 
containing plasmid DNA was transferred to a new 1.7 mL microcentrifuge tube containing 
1 mL ice-cold 100% ethanol , 1/10th volume NAoAC pH 5.2, and 1 µL glycogen and mixed 
by inversion. Samples were incubated at -20ºC for 30 min to precipitate the DNA. The 
DNA was pelleted by centrifuging samples at 14,000 rpm for 10 min. DNA pellets were 
washed twice with 70% ethanol and centrifuged at 14,000 rpm for three min. The 
supernatant was removed and tubes were inverted to dry DNA pellets for 10-15 min. 
2.1.3 Cloning  
For routine cloning, a desired fragment was PCR amplified and electrophoresed on an 
agarose gel containing ethidium bromide for excision and gel extraction of the 
appropriately sized product. DNA was visualized by exposing the gel to UV light. Gel 
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extractions were performed using the QIAquick gel extraction kit (QIAGEN) according to 
manufacturer’s instruction and re-suspended in 30 µL elution buffer provided with the kit. 
Next, plasmid DNA and the gel extracted insert fragments were digested with restriction 
endonucleases (New England Biolabs) to expose complimentary ends. Generally, 1-5 µg 
plasmid or 30 µL insert were digested overnight at 37ºC. Following digestion, the plasmid 
DNA was eletrophoresed on an agarose gel containing ethidium bromide for excision and 
gel extraction of the linearized vector. Gel extracted insert DNA was purified by 
phenol/chloroform extraction. Purified linearized vectors and insert DNA were 
subsequently ligated in a 10 µL reaction consisting of 1:3 vector to insert ratio, 1 µL T4 
DNA ligase buffer, 1 µL T4 DNA ligase, and brought up to volume with sterile water. 
Ligation reactions were incubated at 16ºC for 4 h and 4ºC overnight in a thermocycler.  
2.1.4     Polymerase Chain Reaction (PCR) 
2.1.4.1     PCR for Cloning 
Expand Long Template PCR System (Roche) was used for cloning. Generally, 1 µg DNA 
was used in a 25 µL reaction containing 2.5 µL 10X buffer 2, 2 µL 2.25 mM dNTP mixture, 
1 µL 25 µM primer mix, 0.5 µL Taq polymerase, and sterile water to a final volume of 25 
µL. A thermocycler was then used to run the PCR program particular to the side of the 
fragment being cloned and the primers being used. Generally, the cycle was set up as 
follow: 94ºC for 4 min, 94ºC for 30 sec, 58ºC for 30 sec (temperature varies based on 
primer melting temperature), and 68ºC for 30 sec (time varies with product size being 
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amplified- generally 1 minute per kb). Steps 2-4 were repeated 34 times, and a final 
extension was performed for 5 min at 68ºC. Samples were stored at -20ºC.  
2.1.4.2     Site-directed Mutagenesis 
To generate point mutations in the Pten promoter four primers were designed 
(Invitrogen™). The two outer primers contained bases at the 5’ end to complement vector 
restriction sites and amplified the entire target sequence. The two inner primers overlapped 
at the MEF2 site and contained the mutant bases. Three separate reactions were performed: 
The most upstream outer primer and the reverse mutant primer were used to amplify the 
first half of the mutant Pten promoter from genomic rat DNA. The most downstream outer 
primer and the forward mutant primer were used to amplify the second half of the mutant 
Pten promoter from genomic rat DNA. PCR reactions were electrophoresed on an agarose 
gel containing ethidium bromide and visualized with UV. PCR products were excised and 
gel extracted with the QIAquick gel extraction kit (QIAGEN) according to manufacturer’s 
instruction. The third PCR reaction was performed with the two outermost primers 
containing the restriction sites and 2 µL gel purified product from reactions 1 and 2. The 
PCR product from the third reaction was electrophoresed on an agarose gel, extracted, and 
cloned in the pGL3promoter vector.   
2.1.4.3     Quantitative Reverse Transcription Real Time PCR (qRT-PCR) 
RNA from knockdown experiments (n ≥ 3) was used to synthesize cDNA using 
reverse transcriptase (M-MLV) with random hexamers (Promega). Quantitative RT-PCR 
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was performed in triplicate wells using Power SYBR® Green Master Mix (Applied 
Biosystems) with the 7900HT Sequence Detection System (Applied Biosystems). 
2.1.5     Plasmids 
The MEF2 overexpression plasmids were kind gifts of Eric Olson (UT Southwestern). The 
MEF2-FLAG overexpression plasmids were generously provided by Tod Gulick (Sanford 
Burnham Medical Research Institute).  
2.2 Cell Culture and Cell-Based Assays 
2.2.1 Cell Maintenance  
COS1, C2C12, HEK293A, and HEK293T cells were grown in DMEM supplemented with 
10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine (growth media) 
and maintained in a humidified incubator at 37ºC with 5% CO2. Cells were split when they 
reached a confluence of 60-70% as follows: Media was aspirated and cells were washed 
once with sterile 1X PBS. The PBS was aspirated, 0.25% trypsin-EDTA was added to cells 
and plates were incubated at 37ºC for 2 min. Media was added to cells and the bottom of 
the plate was squirted to detach any remaining attached cells. Cells were then plated at a 
1:10 or 1:20 dilution.  
2.2.2 Isolation of Neonatal Rat Ventricular Myocytes (NRVMs) 
NRVMs were isolated from approximately ten 2 day-old SASCO Sprague-Dawley 
neonatal rats (Charles River Laboratories). Pups were sacrificed by decapitation, and hearts 
were exposed and removed by cutting down the sternum. Hearts were placed into chilled 
1X HBSS and kept on ice throughout dissection. After dissection, hearts were transferred 
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to a sterile tissue culture hood. The 1X HBSS was removed from the hearts, and hearts 
were placed into a 6 cm dish containing 5 mL pre-chilled 1X HBSS. Ventricles were 
separated from atria, and transferred to a new 6 cm dish containing 5 mL pre-chilled HBSS. 
Ventricles well cut into three pieces using single cuts to minimize tissue damage and 
washed three times with pre-chilled 1X HBSS. After the last wash, ventricles were 
transferred to 25 mL 1X HBSS/0.025% Trypsin and incubated overnight at 4ºC. The next 
day, 10 mL of pre-warmed growth media was added to the ventricle/trypsin mixture and 
incubated in a shaking incubator at 37ºC at 125 rpm for 4 min. The media was removed 
and 10 mL pre-warmed 10 mg/mL collagenase II (Worthington Biochemical) was added 
to isolate individual cardiomyocytes. Hearts were incubated in a shaking incubator at 37ºC 
at 125 rpm for 6 min. The supernatant containing cardiomyocytes was transferred to a new 
50 mL conical tube. This step was repeated seven times, for a total of eight collagenase 
digestions until ventricles were mostly digested and only very small pieces were left. The 
two 50 mL conical tubes containing the supernatant and cardiomyocytes were centrifuged 
at 1,000 rpm for 4 min to pellet the cells. The supernatant was carefully aspirated, and 
cardiomyocytes were washed by resuspension in 20 mL pre-warmed growth media. 
Cardiomyocytes were centrifuged at 1,000 rpm for 4 min to pellet the cells. The supernatant 
was removed, and NRVMs were resuspended in 10 mL growth media for a total of 20 mL 
media containing cells. The 20 mL cells were pre-plated on a 10 cm tissue culture dish and 
incubated in a tissue culture incubator for 45 min to 1 h at 37ºC to remove fibroblasts. Pre-
plating was repeated a second time to enrich for cardiomyocytes, for a total of two one 
hour pre-plates. The cell suspension containing NRVMs was transferred to a new 50 mL 
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conical tube and cell density was counted using a hemocytometer. Cells were plated in 
growth media at a density of 4 x 106 cells/10 cm dish on gelatinized dishes. After 24 hours 
in culture, cells were washed with 1X PBS and switched to 0.5X Nutridoma-SP (Roche) 
in DMEM, a low serum media.  
2.2.3 Polyethylenimine (PEI) Transfections  
Transfections were carried out using PEI (Polysciences, Inc.) at a 6:1 PEI to DNA ratio. 
For reporter assays, COS or HEK293T cells were seeded in a 6-well plate at a density of 
100,000 cells per well. To transfect, PEI was mixed with serum free DMEM and incubated 
at room temperature for five minutes. This mixture was then added to total DNA and 
incubated at room temperature for 15 min. The DNA:PEI:DMEM mixture was added to 
cells and incubated for 48 h.  
2.2.4 Viral Transduction 
The Mef2a shRNA adenovirus was used at a multiplicity of infection (MOI) of 25 for all 
assays. The Mef2b, -c, and –d shRNA adenoviruses were used at an MOI of 50 for all 
assays performed in C2C12 cells. β-gal, MEF2A, C, D, and MEF2-VP16 overexpression 
adenoviruses were generously provided by Jeff Molkentin (Children's Hospital, Cincinnati, 
OH) and Ken Walsh (Boston University Medical School), and were used at an MOI of 50 
in C2C12 cells. Cells were harvested for RNA or protein four days post-transduction after 
three days of differentiation. The shlacZ shRNA, Mef2d shRNA, β-gal and MEF2D 
overexpression adenoviruses were used at an MOI of 25 for all assays performed in 
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NRVMs. Cells were harvested for RNA and protein three days post-transduction. Viability 
assays were performed with cells harvested three, five, or seven days post-transduction. 
2.2.5 Luciferase Assays 
Cells were harvested for luciferase activity assay 48 hours following transfection. Cells 
were rinsed gently with 1X PBS and were lysed in 1X passive lysis buffer (Promega) by 
shaking for 15 min at room temperature. Cell lysates were mixed by pipetting well contents 
up and down, and transferred to a 1.7 mL microcentrifuge tube. To measure Firefly 
Luciferase activity, 10 µl cell lysate was placed into a new 1.7 mL microcentrifuge tube 
and mixed with 50 µl luciferase assay reagent (Promega). Samples were mixed by pipetting 
up and down ten times, and readings were taken on a luminometer. Luciferase readings 
were normalized to β-gal activity to control for transfection efficiency. Fold change was 
calculated by dividing normalized values by the negative control value. The negative 
control consisted of empty vector backbones, and was set to one.   
2.2.6 CellTiter-Blue® Cell Viability Assay 
NRVMs were plated in a 24-well format at a density ranging between 2,500- 80,000 cells 
per well. Cells were transduced with adenovirus to modulate MEF2D levels, and 10 µL 
CellTiter-Blue® reagent (Promega) was added to each well 2, 4, or 6 days after 
transduction. Plates were incubated for 24 h at 37ºC in a tissue culture incubator, and 
fluorescence was measured at 560/590 nm using a Perkin Elmer Victor3 plate reader.  
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2.2.7 PI3K/AKT Inhibition 
The PI3Kα/δ inhibitor GDC-0941 (Sellac Chemicals) was generously provided by 
Geoffrey Cooper (Boston University). GDC-0941 was added to NRVMs at a final 
concentration of 10 µM, on the same day of transduction with shRNA adenovirus.  
2.2.8 β-galactosidase Activity Assay 
Cells were harvested for luciferase activity assay 48 hours following transfection. Cells 
were rinsed gently with 1X PBS and were lysed in 1X passive lysis buffer (Promega) by 
shaking for 15 min at room temperature. Cell lysates were mixed by pipetting well contents 
up and down, and transferred to a 1.7 mL microcentrifuge tube. β-galactosidase activity 
assay was performed using the J.H. Miller method, by incubating whole cell extracts with 
reaction mixture containing 15 µL Z-Buffer (60 mM Na2HPO4.7H2O, 40 mM 
NaH2PO4.H2O, 10 mM KCl, 1 mM MgSO4, 50 mM β-mercaptoethanol) 16.5 µL 
ONPG (8 mg/mL) , and  brought up to 150 µL with water. Samples were incubated in a 
37ºC water bath until a slight yellow color appeared. The reaction was stopped by adding 
250 µL 1M Na2CO3. Absorbance was measured at 415 nm and values were used to 
normalize Luciferase readings.  
2.3 shRNA Design and Expression 
2.3.1 shRNA Design 
shRNA sequences targeting the C-terminal region of individual Mef2 transcripts 
were generated using the BLOCK-iT RNAiTM designer system (Invitrogen) freely 
available online. Human, mouse, and rat mRNA sequences were analyzed for conservation 
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of the proposed shRNA sequences. shRNAs which targeted multiple Mef2 isoforms, or 
were found within alternatively spliced exons were excluded. Four potential candidate 
shRNA were chosen for each MEF2 isoform. The chosen shRNAs targeted all isoforms of 
a given MEF2 factor.  
2.3.2 shRNA Cloning and Selection  
Four candidate shRNA sequences for each Mef2 isoform were cloned into the 
pENTR/U6 vector.  The efficacy of these newly designed MEF2 shRNAs was examined 
in COS cells co-transfected with each shRNA along with either MEF2A-FLAG, MEF2B-
FLAG, MEF2C-FLAG, or MEF2D-FLAG. Two days after transfection, cells were 
harvested for protein and Western blot analysis was performed to demonstrate specificity 
of these shRNAs. After confirming that these shRNAs robustly knocked down the 
expression of the respective MEF2 protein without affecting the expression of the other 
MEF2 family members, shRNAs packaged into adenovirus for transduction in C2C12 
cells and NRVMs. To achieve adenoviral packaging, shRNAs were cloned into the 
pAd/BLOCK-iTTM-DEST RNAi Gateway Vector (Invitrogen) and transfected into 
HEK293A cells, a cell line containing the molecular machinery required to amplify and 
package pAd Mef2d shRNA into adenoviral particles. 
2.3.3 Generation of Crude Adenovirus 
Adenoviral expression clones were digested with PacI overnight. The reaction was 
phenol/chloroform extracted and transfected into HEK293A cells plated at a density of 
35,000 cells/35 mm dish. The media was changed the following day, and cells were 
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transferred to a 10 cm dish 24 hours later. Media was replaced every 2-3 days until 
cytopathic effects (CPE) were visible as patches of rounded dying cells ~ 7-10 after 
transfection. Cells and the media were harvested when ~80-90% of all cells had died and 
lifted off the plate. The sample was subjected to three freeze-thaw cycles at -80ºC for 30 
min and 37ºC for 15 min. Cell debris was pelleted by centrifuging the sample at 3,000 rpm 
for 15 min at room temperature. The supernatant was aliquoted into cryovials and stored 
at -80ºC. This initial crude stock was used in future amplifications, in which 100 µL of the 
initial crude stock was added to 50 x 10 cm plates of HEK293A cells and incubated until 
CPE was evident (~2-3 days). Approximately 500 mL of crude stock was generated.  
2.3.4      Adenovirus Purification 
2.3.4.1     Cesium Chloride Purification  
Crude viral stocks were thawed in a water bath at 37ºC, and transferred to 250 mL bottles. 
NP-40 was added to a final concentration of 0.5% and bottles were gently shaken for 10 
min at room temperature to lyse cells. Cell debris was pelleted by centrifuging samples at 
20, 000 g for 15 min. The supernatant containing viral particles was transferred to a 1 L 
flask and 0.5 volume of 20% PEG 8000/2.5 M NaCl was added and shaken on ice in a cold 
room overnight to precipitate viral particles. The supernatant containing precipitated viral 
particles was transferred to 250 mL bottles and centrifuged at 20, 000 g for 15 min to pellet 
viral particles. The supernatant was mixed with a 10% bleach solution and discarded. Viral 
precipitates were resuspended in a small amount of 1X PBS (~3-4 mL total) and transferred 
to a 15 mL conical tube. CsCl was added to a final density of 1.34 g/mL, and samples were 
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brought up to a final volume of 5 mL with 1X PBS. The 5 mL sample was loaded into an 
ultracentrifuge tube and centrifuged in a Vti90 rotor at 70,000 rpm overnight at 18ºC. The 
viral band was extracted using a 22 gauge needed and 1 mL syringe and transferred to 1.7 
mL a microcentrifuge tube kept on ice. Viruses were desalted by dialysis in autoclaved 10 
mM Tris-HCl pH 8.0, 1 mM MgCl2, and 10% glycerol at 4 º C for two h. Three rounds of 
dialysis were completed. The solution containing the virus was aliquoted and frozen at -
80ºC.  
2.3.4.2     Titering of Adenovirus 
Viral titer was determined using the End Point Dilution Assay described in the Adeno-X™ 
Tet-off® & Tet-On® Expression System user manual (Clontech). Briefly, HEK293A cells 
were plated in two 96-well plates at a density of 10,000 cells per well 24 h before beginning 
titration. On the first day of titration, 1:10 serial dilutions of the virus were prepared ranging 
from 10-5-10-12 for a total of eight concentrations, one per row A-H. The virus containing 
media (100 µl/well) was added to columns 1-10 of rows A-H. Columns 11 and 12 were 
used as the negative control and 100 µl virus free growth media was added to each well in 
these columns. Plates were incubated for 10 days and each well was scored for CPE. The 
fraction of CPE-positive wells for each dilution was added together and this number was 
used to calculate titer based on the Spearman-Karber method where titer equals 10X+0.8 
pfu/mL 
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2.4 RNA Techniques 
2.4.1 RNA isolation 
RNA was isolated from samples using TRIzol® Reagent (Invitrogen) according to the 
manufacturer’s instructions. Briefly, cells were washed once with 1X PBS and an 
appropriate volume of TRIzol® Reagent was added directly to cells. Typically, 500 µL 
TRIzol was added for a 600 mm dish. Cells were scraped in the TRIzol, transferred to 1.7 
mL microcentrifuge tubes, and incubated at room temperature for five min. RNA was 
processed for phase separation and RNA precipitation according to manufacturer’s 
instructions. RNA pellets were washed twice with 70% ethanol and allowed to dry inverted 
for 10-15 min. RNA was re-suspended by pipetting up and down in 30 µL sterile water. 
RNA integrity was determined by gel electrophoresis and was visualized by exposing the 
gel to UV light. Concentrations were determined using 2 µL RNA to measure optical 
density with a NanoDrop 1000 Spectrophotometer (Thermo Scientific). Samples were kept 
on ice at all times and stored at -80ºC.  
2.4.2 Microarray 
For C2C12 cells: Seventy-two hours after induction of differentiation, total RNA 
from shlacZ (n = 6), shMef2a (n = 6), shMef2b (n =6), shMef2c (n = 6), and shMef2d (n = 
6) C2C12 myotubes was prepared by TRIzol® isolation (Invitrogen). Samples were pooled 
in sets, for a total of three biological replicates per condition. Samples were hybridized to 
the Mouse GeneChip® Gene 1.0 ST array (Affymetrix) at the Boston University 
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Microarray Facility (n = 3 per shRNA; 15 arrays total). Microarray data are available in 
GEO (NCBI) with accession number GSE63798. 
For NRVMs: Seventy-two hours after transduction, total RNA from shlacZ and 
shMef2d (n = 6) NRVMs was prepared by TRIzol® isolation (Invitrogen). Equal amounts 
of RNA from six biological replicates were pooled per condition. Samples were hybridized 
to the Rat GeneChip® Gene 1.0 ST array (Affymetrix) at the Boston University Microarray 
Facility (n = 1 per shRNA; 2 arrays total). 
2.5 Protein Techniques   
2.5.1 Protein Isolation  
Adherent cells in tissue culture plates were first washed with 1X PBS, and then scraped off 
the bottom of the plate into 1X PBS. Cells were pelleted by centrifugation at 13,000 rpm 
for five min at room temperature. Pellets were dounce homogenized using a sterile pestle 
in ELB buffer (50 mM HEPES, 250 mM NaCl, 5 mM EDTA, 0.1% NP-40, 1 mM PMSF, 
1 mM DTT, 1X protease inhibitors) (Roche Diagnostics). Homogenized samples were 
placed on ice for 10 min, and centrifuged at 13,000 rpm for 10 min at 4ºC to separate the 
protein containing supernatant from cell debris. The supernatant containing protein was 
collected and stored at -80ºC.  
2.5.2 Bradford Assay 
Stocks of BSA were prepared as standards for protein concentration (1 µg, 0.5 µg, 2.5 µg, 
0.25 µg, 0.1 µg, 0.05 µg, and 0.02 µg). 10 µL of each protein standard and protein sample 
were mixed with 200 µL 1X Bio-Rad Bradford Protein Assay Dye Reagent (Bio-Rad 
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Laboratories). Absorbance was measured at 595 nm and protein concentrations were 
determined using the standard curve obtained with the BSA standard dilutions.  
2.5.3 Western Blot 
Approximately 10-25 µg protein was mixed with SDS loading buffer and electrophoresed 
on a polyacrylamide gel composed of a lower separating gel (10% acrylamide, 375 mM 
Tris-HCl pH 8.8, 0.1% SDS) and an upper stacking gel (5% acrylamide, 125 mM Tris-HCl 
pH 6.8, 0.1% SDS). Protein samples were loaded and electrophoresed at 190 volts in 1X 
SDS running buffer (25 mM Tris-HCl, 190 mM glycine, 0.1% SDS) for the desired run 
length. After electrophoresis, the gel was equilibrated for 10 min in 1X transfer buffer (20 
mM Tris, 150 mM glycine) containing 20% methanol. Proteins were transferred to an 
Immuno-blot PVDF membrane (Bio-Rad) by electroblotting overnight at the lowest setting 
(~20 volts). After transfer, the blot was blocked in the appropriate blocking solution (5% 
nonfat dry Carnation milk in 1X TBS buffer, or 5% BSA in 1X TBS/0.1% Tween for 
phospho-specific antibodies) for 1 h at room temperature. Membranes were then incubated 
overnight at 4ºC with the appropriate antibody diluted in either 5% nonfat dry Carnation 
milk in 1X TBS buffer, or 5% BSA in 1X TBS/0.1% Tween for phospho-specific 
antibodies. The membrane was washed for 5 min in 1X TBS/ 0.1% Tween three times, 
then incubated with the appropriate secondary antibody conjugated to HRP in 1X TBS/ 
0.1% Tween for 1 h at room temperature. The membrane was again washed for 5 min in 
1X TBS/ 0.1% Tween three times and treated with Western Lighting Chemiluminescent 
Reagent (Perkin-Elmer) for 1 min. Protein was visualized by exposing the membrane to X-
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ray film. Antibodies included: anti-GAPDH (1:1000; Santa Cruz), anti-MEF2 (1:1000; 
Santa Cruz), anti-MEF2C (1:1000; Sparrow Biosciences), anti-MEF2D (1:1000: BD 
Biosciences), anti-FLAG (1:10,000; Sigma), anti-α-tubulin (1:1000; Sigma), anti-MF-20 
(1:200; supernatant, DSHB). Anti-PCNA (1:2000; Cell Signaling), PTEN (1:1000; Cell 
Signaling), AKT (1:1000: Cell Signaling), pAKT T308 (1:1000: Cell Signaling), pAKT 
S473 (1:1000: Cell Signaling), Cyclin D1 (1:1000: Cell Signaling), Cyclin D3 (1:1000: 
Cell Signaling), CDK2 (1:1000: Cell Signaling). Blots were incubated with horseradish 
peroxidase-conjugated secondary antibodies (1:10,000; Sigma) and reacted with Western 
Lightning Chemiluminescent Reagent (Perkin Elmer). 
2.5.4 Caspase-3 Activity Assay 
The fluorogenic caspase-3 substrate Ac-DEVD-AMC (BD Biosciences) was resuspended 
in DMSO to a final 1 mM concentration. Aliquots were kept at -80ºC for long term storage. 
For the assay: NRVM protein lysates were mixed with Ac-DEVD-AMC to a final 50 µM 
concentration. Samples were incubated for 1 h in a 37ºC water bath to allow Caspase-3- 
mediated cleavage of the compound. Fluorescence was measured at 440/460 nm using a 
Perkin Elmer Victor3 plate reader. Caspase-3 activity was normalized to total protein level 
determined using a Bradford protein assay (Bio-Rad).  
2.6 Electrophoretic Mobility Shift Assay (EMSA) 
Oligonulceotides were designed in both the sense and antisense direction to span the 
binding site to be tested with six nucleotides on each side and flanked by a 5’ AAGG starter 
sequence (Table 2.3). An annealing reaction was made to contain 20 ng of each sense and 
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antisense primer stock, NEB buffer 2, and water to volume. Samples were incubated at 
65ºC for 20 min on a heat block, the heat block was turned off, and allowed to return to 
room temperature with the samples in it (~ 2-3 ). Annealed olinonucleotides were 
radioactively end-labeled using the Rad-Prime kit (Invitrogen). Briefly, 15 µL dH2O, 2 µL 
annealed oligo, 2.5 µL 10X Klenow buffer, 2.5 µL ATG dNTP mix, 2 µL 32P-dCTP, and 
1 µL Klenow enzyme were mixed and incubated at room temperature for 2 h. Samples 
were purified over a Sephadex G-25 Quick-Spin column (TE) for radiolabeled DNA 
purification (Roche). Labelling efficiency was measured with liquid scintillation using 1 
µL the labeling reaction. Approximately 50,000 cpm of labeled oligonucleotide (probe) 
were used in the gel shift reaction. In vitro-translated mouse MEF2D (rabbit reticulocyte 
lysate; Promega) or nuclear extracts from NRVMs were used for gel shift assays. The 
mutant MEF2 site was generated in the same manner as the mutant Pten reporter. 
Supershift assays were performed with anti-MEF2D antibodies (BD Biosciences). 
Competitions were performed with 100-fold molar excess of unlabeled probe. Gel shift 
reactions were fractionated on 5% non-denaturing polyacrylamide gels, dried, and exposed 
to a phosphor-imaging screen (Amersham Biosciences). 
2.7 Immunofluorescence 
2.7.1 Immunocytochemistry 
Cells were cultured on sterilized coverslips coated with Matrigel, and transduced with the 
appropriate shRNA adenoviruses. Cells were washed with 1X PBS and fixed in 4% 
paraformaldehyde at the appropriate time-point. Next, cells were blocked in Mouse on 
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Mouse Blocking Solution (Vector Labs) for one hour at room temperature. Cells were 
incubated with primary antibodies diluted in antibody dilution buffer (1X PBS/1% BSA/ 
0.3% Triton X-100) overnight at 4ºC. The following day, cells were washed for five 
minutes in 1X PBS three times. Cells were incubated with fluorochrome-conjugated 
secondary antibody diluted in antibody dilution buffer for two hours at room temperature. 
Finally, cells were washed for five minutes in 1X PBS three times, and mounted on slides 
with VECTASHIELD Mounting Medium with DAPI (Vector Labs). Slides were sealed 
with a thin layer of nail polish and stored at 4ºC in the dark. Images were taken with an 
Olympus DSU Spinning Disc confocal microscope. Antibodies included: α-actinin (1:500; 
Sigma), FKHRL-1 (1:200; Millipore), Ki67 (1:200; Abcam), Alexa fluor 488 donkey anti-
mouse H+L (1:200; Invitrogen), Alexa fluor 555 donkey anti-rabbit H+L (1:500; 
Invitrogen).  
2.7.2 TUNEL Assay 
Cells were cultured on sterilized coverslips coated with Matrigel, and transduced with the 
appropriate shRNA adenoviruses. Cells were washed with 1X PBS and fixed in 4% 
paraformaldehyde at the appropriate time-point. TUNEL assay was performed using the 
DeadEnd™ Fluorometric TUNEL System (Promega) according to manufacturer’s 
instructions. Coverslips were mounted on slides with VECTASHIELD Mounting Medium 
with DAPI (Vector Labs). Slides were sealed with a thin layer of nail polish and stored at 
4ºC in the dark. Images were taken with an Olympus DSU Spinning Disc confocal 
microscope. 
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2.7.3 EdU Incorporation Assay 
Cells were cultured on sterilized coverslips coated with Matrigel, and transduced with the 
appropriate shRNA adenoviruses. Cells were washed with 1X PBS and fixed in 4% 
paraformaldehyde at the appropriate time-point. EdU incorporation assay was performed 
using the Click-iT® EdU Alexa Fluor® 555 Imaging Kit (Invitrogen) according to 
manufacturer’s instructions. Coverslips were mounted on slides with VECTASHIELD 
Mounting Medium with DAPI (Vector Labs). Slides were sealed with a thin layer of nail 
polish and stored at 4ºC in the dark. Images were taken with an Olympus DSU Spinning 
Disc confocal microscope. 
2.8 Computational Analysis 
2.8.1 Computational Pathway Analysis  
Statistically distinct gene sets sensitive to individual MEF2 isoforms were analyzed 
using three independent pathway analysis algorithms. Gene Ontology (GO) term and 
KEGG pathway analyses were performed through the DAVID bioinformatics database 
(Huang da et al., 2009a, b). Ingenuity Pathway Analysis (Ingenuity®Systems) was used to 
determine the canonical cellular pathways associated with each uniquely sensitive gene set. 
2.8.2 MEF2 Binding Site Variation Analysis  
MEF2 binding site comparisons were performed by extracting putative MEF2 
binding sites from the proximal promoter regions (5 kb upstream of the putative 
transcriptional start site) of gene sets uniquely sensitive to each MEF2 isoform using the 
FIMO tool from the MEME suite (Grant et al., 2011). Extraction was performed by scoring 
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10 base pair motifs against the MEF2 motif stored in the JASPAR database (MA0052.1) 
using a p-value threshold of less than 0.0001. The output position-weight matrices were 
then used to compile a sequence logo using the WebLogo (Crooks et al., 2004). 
2.8.3 De novo Motif Discovery  
Transcription factor binding motif enrichment analysis was performed on the 
proximal promoter region of genes preferentially sensitive to each MEF2 isoform using 
MatInspector from the Genomatix software suite (Quandt et al., 1995). A default 
background consisting of a cross-section of genomic promoter sequences was used to 
discriminate between enriched features and non-specific promoter regions. The resulting 
transcription factor motifs were then sorted by Z-score. Motifs with a Z-score of greater 
than or equal to 2 were considered to be enriched. Additional data for each enriched motif 
were extracted from the Genomatix MatBase and NCBI databases. 
2.9 Statistical Analysis  
All numerical quantification is representative of the mean ± standard error of the 
mean (S.E.M.) of at least three independently performed experiments. Statistically 
significant differences between two populations of data were determined using Student’s t-
test. P-values of ≤0.05 were considered to be statistically significant. The technical quality 
of the arrays performed on was evaluated using Relative Log Expressions (RLE) and 
Normalized Unscaled Standard Error (NUSE). RLE and NUSE values >0.1 and >1.05, 
respectively, are considered out of normal limits. All arrays had median values within the 
limits of these tests. Microarray data was normalized using the Robust Multiarray Average 
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algorithm and were log2 transformed by default. Knockdown efficiency was determined 
by calculating a fold change for each MEF2 isoform knockdown relative to the shlacZ 
control. Significant dysregulation of gene expression was determined using a one-way 
analysis of variance (ANOVA). The Benjamini-Hochberg False Discovery Rate correction 
was then applied to obtain corrected q-values, and a q-value threshold of less than or equal 
to 0.05 was used to determine significant dysregulation. Tukey’s Honest Significant 
Difference (HSD) post hoc test was performed to identify significantly dysregulated genes 
and correct for multiple testing error across all inter-group comparisons. A corrected q-
value of 0.05 was used to determine statistically significant gene dysregulation among 
groups. 
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Table 2.1. List of mouse qRT-PCR primers used to validate the C2C12 comparative 
microarray in chapter three.  
 
 
 
 
 
 
Gene Forward Reverse 
Gapdh 5’ TGGCAAAGTGGAGATTGTTGCC 5’ AAGATGGTGATGGGCTTCCCG 
Cdkn1c 5’ CCAATGCGAACGACTTCTTCGC 5’ AACTAACTCATCTCAGACGTTTGCGC 
Sept4 5’ TACACTCATGGTGGCAGGAGAATCTG 5’ CACTCTGTGTTGTTGACTGCATCC 
Hspb7 5’ GCTGAGAAGCTGGCAGCTGATG 5’ ATCTCAGTCCGGAAGGTCTGCTG 
Myom1 5’ CTACTCTGGACGGCAAGTGCAC 5’ GTGGTCCGTTTGGAGGTTGC 
Stc2 5’ CTGCAGAACACAGCGGAGATCC 5’ CTGGGCATCGAATTTTCCAGCGT 
Tex16 5’ CTTCTTGCCCTTTCAAGGTGT 5’ TACCTGTTTGGAGTCTGAGCTGAA 
Selp 5’ TACACAGCCTCCTGCCAGGA 5’ CTGAAGGTGCACTGTGAGTTGAAGG 
C1ql1 5’ GGTCACCAACCTAGGCAACAACTAC 5’ CTCCATCCAGCTTGATGAAGACCTC 
Bace2 5’ ACTCAGAGAGCTCCAGCACATACC 5’ GCCAAAGCAGCATAAGCAAGTCC 
Pi16 5’ CTGCAGATGAGGTGGGATG 5’ GCCGTGCTGAAATTGTAATACTC 
Themis 5’ CTACGGACGACCTTTTTGAAAT 5’ CTAAGATCCTCGAAGCCTGGTA 
Glipr1 5’ ACTCAGGTTGTTTGGGCAGACAG 5’ TGCAGAGACTGTTGAGACACTTGTCA 
Cpa4 5’ GTACACGCAAAGCCAGAACC 5’ CCATGGTACACTTCAGAGCAAG 
Fam78a 5’ AGCAGGGCATGTCTAGCTGG 5’ CACGTGGTGAAGCTCTGGTC 
Ppp1r3a 5’ GCTAGACTTGATGATAAACCAACGG 5’ CCCATGAACAAGTCAGTGTTGA 
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Table 2.2. List of rat qRT-PCR primers used in NRVM studies.  
Gene Forward Reverse 
Gapdh 5’ TGGCAAAGTGGAGATTGTTGCC 5’ AAGATGGTGATGGGCTTCCCG 
Mef2a 5’ GAACTCAGTGTGCTCTGTGACTGTGAG 5’ GCCAGTGCTTGGTGGTCTCT 
Mef2b 5’ GAAAGAAAGCCGCTCTGCACAG 5’ ACCTTCTGGCCCCTCCTCCATA 
Mef2c 5’ CAGGGACGAGAGAGAGAAGAAAC 5’ CAATCTTTGCCTGCTGATCATTAG 
Mef2d 5’ CTTTCCTCTCTGGCACTAAGGAC 5’ CCAGTCTATAACTCTGCATCATC 
Mcm3 5’ AACCCGTTCCAAGGATGTCTTTGAG 5’ GGTTTCCTGGTCTGTGGTGACG 
Mcm5 5’ GGACATGATGCTGGCCAAACATGT 5’ GGCTGCAGTTTCATCTTGCTGAGG 
Mcm6 5’ GACTTCCTGGAAGAGTTCCAGGG 5’ CGATCCTGGAGGAAGTGAGCTC 
Pcna 5’ CGTGAACCTCACCAGCATGTCC 5’ CCAAGTTGCTCAACGTCTAAGTCCA 
Ccne1 5’ CCAGGATAGCAGTCAGCCTTGG 5’ TGCTCTCATCCTCGCCTGC  
Ccne2 5’ AATTGTTGGCCACCTGTACTGTCTG 5’ ACTTCACAGACCTCTAAAAGCCAGTCT 
Pten 5’ACTGCAGAGTTGCACAGTATCCTT 5’ GCCTCTGACTGGGAATAGTTACTCC 
E2f1 5’ ACCCAGGGAAAGGTGTGAAATCT 5’ ACTTCTTGGCAATGAGTTGGAT 
E2f2 5’ AAGCCCGAAAACCCCTAAGTCT 5’ TACCCACTGGATGTTGTTTTTG 
E2f3 5’ AGGAGCGAGAGATGAGAAAGG 5’ GTGGTGAGGATCTGGATGTACG 
E2f4 5’ GACAGCTGAGATTGCAGTGAGTGG 5’ GGTTGGGTCCAGATGAACTGCT 
E2f5 5’ GTATCCAGTGGAAGGGTGTAGGTG 5’ GCAACTGCAGATGTCTTCGTGA 
Apaf1 5’ AGTCAGGCCACTCAATATCAACGAG 5’ AAATGAAGTGTTTCCACCGTCT 
Casp8 5’ ACTCGGCGACAGGTTACAGC 5’ CTTCCTGCAGCCTCTGAAATAG 
Xiap 5’ CACTTGGGGAATCTGTGGTAAGAAC 5’ TGCAATCAGAACCTCAAGTGAT 
Cdkn2b/p15 5’ CCGATCCAGGTCATGATGATGGG 5’ TCAATCTCCAGTGGCAGCGTG 
Cdkn2a/p16 5’ CAGGTAGTGGATTTGGGCAACGTC 5’ TCACCTGGGCGTGCTTGA 
Cdkn2c/p18 5’ GGAGAACTGCGCTGCAGGTTATG 5’ CCTCCATCAGGCTGATGACCTCAT 
Cdkn2d/p19 5’ GACGGCCTTGCAGGTCATGAT 5’ GCGTCCTTGTGATGGAGATCAGATTC 
Cdkn1a/p21 5’ GTGATATGTACCAGCCACAGGCAC 5’ GCTCAGGTAGATCTTGGGCAGC 
Cdkn1b/p27 5’AAGAGCGCCTGCAAGGTG 5’ TAATTCGGAGCTGTTTACGTCTGGC 
Cdkn1c/p57 5’ATGGGCATGTCCGACGTGTAC 5’ GTAGAAGGCGGGCACAGACT 
 
Table 2.3. List of oligonucleotides used for EMSA. The wild-type and mutant MEF2 
binding sites are underlined.  
Probe Sense Antisense 
-4596 Pten MEF2 5’ AAGGCATCAACTATTTATACTATCCA 5’ AAGGTGGATAGTATAAATAGTTGATG 
-4596 Pten MUT 5’ AAGGCATCAACTAGGGGTACTATCCA 5’ AAGGTGGATAGTACCCCTAGTTGATG 
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Chapter 3: MEF2 factors regulate distinct gene programs in mammalian skeletal 
muscle differentiation 
This research was originally published in the Journal of Biological Chemistry.  
Estrella, NL. Desjardins, CA. Nocco, SE. Clark, AL. Maksimenko, Y. Naya, FJ. MEF2 
factors regulate distinct gene programs in mammalian skeletal muscle differentiation. J 
Biol Chem.2015; 290:1256-1268. © by The American Society for Biochemistry and 
Molecular Biology. 
 
3.1 Introduction 
Skeletal muscle differentiation requires precisely coordinated transcriptional 
regulation of diverse gene programs that ultimately give rise to the specialized properties 
of this cell type. In Drosophila this process is controlled, in part, by MEF2, the sole 
representative member of an evolutionarily conserved transcription factor family. By 
contrast, vertebrate MEF2 is encoded by four distinct genes, Mef2a, -b, -c, and –d, making 
it far more challenging to link this transcription factor to the regulation of specific muscle 
gene programs. Here we have taken the first step in molecularly dissecting vertebrate 
MEF2 transcriptional function in skeletal muscle differentiation by depleting individual 
MEF2 proteins in myoblasts. Whereas MEF2A is absolutely required for proper myoblast 
differentiation, MEF2B, C, and D were found to be dispensable for this process. 
Furthermore, despite the extensive redundancy, we show that mammalian MEF2 proteins 
regulate a significant subset of non-overlapping gene programs. These results suggest that 
individual MEF2 family members are able to recognize specific targets among the entire 
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cohort of MEF2-regulated genes in the muscle genome. These findings provide 
opportunities to modulate the activity of MEF2 isoforms and their respective gene 
programs in skeletal muscle homeostasis and disease. 
3.2 MEF2 knockdown: shRNA design and specificity  
To address the roles of the mammalian MEF2 transcription factors in skeletal muscle 
differentiation we depleted each protein in C2C12 myoblasts using isoform-specific short 
hairpin RNA (shRNA) adenoviruses. These shRNAs were designed to target all mRNA 
transcripts generated from each Mef2 gene. Previously, we described the specific and 
robust knockdown of MEF2A and MEF2C using shRNA adenoviruses (Ewen et al., 2011; 
Snyder et al., 2013). We subsequently generated shRNAs to specifically target MEF2B 
(Fig. 3.1A) and MEF2D (Fig. 3.1D). The efficacy of these newly designed MEF2 shRNAs 
was examined in COS cells co-transfected with each shRNA along with either MEF2B-
FLAG or MEF2D-FLAG. These shRNAs robustly knocked down the expression of the 
respective MEF2 protein without affecting the expression of the other MEF2 family 
members, demonstrating the specificity of these shRNAs (Fig. 3.1B and E). The MEF2B 
and MEF2D shRNAs were subsequently packaged into adenovirus for transduction in 
C2C12 cells. Transduction of MEF2B- and MEF2D-specific shRNA adenoviruses robustly 
knocked down the expression of the respective endogenous MEF2 factor but did not 
deplete the expression of the other MEF2 family members (Fig. 3.1C and F). 
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3.3 MEF2A knockdown, but not Mef2b, -c, or –d, blocks differentiation 
The four mammalian MEF2 factors display different temporal expression patterns in 
C2C12 differentiation (Ramachandran et al., 2008b; Snyder et al., 2013). Therefore, we 
focused our analysis of the individual MEF2 isoform knockdowns on differentiation day 
3, as this reflects the time at which the four MEF2 proteins are co-expressed in myotubes. 
Proliferating C2C12 myoblasts were transduced with the shRNA adenoviruses and on 
differentiation day 3, MEF2-depleted myotubes were evaluated for gross morphological 
defects in the formation of multi-nucleated myotubes. As previously reported by us and 
others, MEF2A depletion resulted in impaired myotube formation and differentiation    
(Fig. 3.2A-C) (Seok et al., 2011; Snyder et al., 2013). By contrast, individual depletion of 
the other MEF2 proteins failed to show any obvious impairment in myotube formation or 
differentiation (Fig. 3.2A-C). These results suggest that, with the exception of MEF2A, the 
remaining MEF2 proteins are dispensable for C2C12 myogenic differentiation. 
We then asked whether depletion of MEF2B, C, or D could modulate the impaired 
differentiation phenotype of MEF2A-deficient C2C12 cells. Individual depletion of the 
other MEF2 proteins in the MEF2A-deficient C2C12 myoblast background resulted in a 
phenotype similar to MEF2A-deficiency alone (Fig. 3.3A upper panels). We subsequently 
knocked down MEF2B, C, and D in combination to investigate the potential redundancy 
of these proteins in C2C12 differentiation. Knockdown of MEF2B and C, MEF2B and D, 
MEF2C and D, or all three MEF2 proteins did not adversely affect C2C12 differentiation 
(Fig. 3.3A lower panels, Fig. 3.3B, C). These results demonstrate that MEF2A is sufficient 
for C2C12 differentiation and that it may play a dominant role in this context 
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3.4 MEF2C and MEF2D cannot compensate for the loss of MEF2A in muscle 
differentiation 
In a complementary set of experiments, we asked whether overexpression of each 
MEF2 protein in C2C12 myoblasts is sufficient to induce a morphological phenotype in 
these cells. For these experiments we used adenoviruses harboring MEF2A, C, and D 
cDNAs, which have been previously described (Xu et al., 2006). Transduction of these 
MEF2 viruses individually in C2C12 myoblasts resulted in an increase of the respective 
MEF2 protein over endogenous levels (Fig. 3.4A). However, overexpression of the 
individual MEF2 isoforms in proliferating C2C12 myoblasts followed by differentiation 
failed to trigger an overt morphological phenotype in these cells (Fig. 3.4B). Curiously, 
contrary to a recent report (Sebastian et al., 2013), acute overexpression of MEF2D did not 
appear to enhance myotube formation in C2C12 cells even though this adenovirus encodes 
the muscle-specific α2 isoform described in that study. 
We next determined whether overexpression of MEF2A, C, or D was capable of 
rescuing the differentiation defect in MEF2A-deficient C2C12 cells. Transduction of 
MEF2C or D adenoviruses failed to rescue myotube formation or differentiation in 
MEF2A-depleted C2C12 cells (Fig. 3.5A, B, and C). By contrast, transduction of MEF2A-
depleted C2C12 cells with MEF2-VP16 adenovirus (Xu et al., 2006), consisting of only 
the MEF2C DNA binding and the VP16 transactivation domains, effectively promoted 
myotube formation and differentiation (Fig. 3.5A, B, and C). Importantly, the rescue by 
MEF2-VP16 strongly suggests that impaired C2C12 differentiation is caused by the 
specific knockdown of MEF2, and not secondary off-target effects caused by the shRNA. 
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It is worth noting that MEF2A overexpression was unable to rescue the MEF2A-deficient 
phenotype because the MEF2A cDNA encoded in this adenovirus is knocked down by this 
shRNA (Fig. 3.6A, and B). 
3.5 MEF2 factors regulate distinct gene programs in skeletal muscle 
The lack of readily observable phenotypes in the individual and combinatorial 
knockdowns of MEF2B, C, and D suggested that these proteins function redundantly to 
each other in C2C12 myotube formation. Furthermore, the inability of MEF2C and D 
overexpression to rescue impaired myotube formation in MEF2A-depleted C2C12 cells 
demonstrates that they are not functionally redundant with MEF2A in this process. 
Therefore, to determine what sets of genes and cellular processes are regulated by 
individual MEF2 proteins in skeletal myotubes we performed global gene expression 
profiling for each knockdown. 
Microarray analysis of C2C12 myotubes depleted of individual MEF2 proteins 
(n=3 arrays for each MEF2 shRNA) resulted in a range of significantly dysregulated genes 
(Fig. 3.7A and B), as determined by a one-way ANOVA using the Benjamini-Hochberg 
False Discovery Rate correction and a threshold q-value less than or equal to 0.05. Using 
these stringent criteria, the most striking difference in the total number of dysregulated 
genes was observed for MEF2A and D knockdowns. As shown in Figure 3.7A and B, 
depletion of MEF2A revealed 4,020 significantly dysregulated genes, whereas MEF2D-
deficiency resulted in only 110 dysregulated genes. A wide disparity was also noted when 
comparing the MEF2A knockdown to that of MEF2B and C, suggesting that MEF2A plays 
a major transcriptional function in C2C12 cells. The microarray results were subsequently 
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validated by qRT-PCR analysis on a subset of the top dysregulated genes (up- and down-
regulated) from each individual knockdown. Most of the genes examined displayed the 
expected dysregulation (Fig. 3.8). 
To identify genes sensitive to a given MEF2 isoform, we compared the various 
dysregulated gene sets to determine the extent of overlapping genes. MEF2-dependent 
genes were designated as isoform-sensitive (or non-overlapping) if they were significantly 
different from each other using the Tukey’s HSD post-hoc test. Based on these strict 
statistical criteria, a subset of genes in each MEF2 knockdown was clearly found to be 
significantly more sensitive to the respective MEF2 isoform compared to the other family 
members. As shown in the Venn diagram (Fig. 3.7B), these non-overlapping dysregulated 
groups included 3248 genes (81% of the total dysregulated by MEF2A) for MEF2A, 126 
genes (12%) for MEF2B, 101 genes (10%) for MEF2C, and 28 genes (25%) for MEF2D. 
This comparative analysis also revealed that many (75-90%) of the genes dysregulated in 
the MEF2B, C, and D knockdowns were dysregulated in one or more of the other MEF2 
depletions. Furthermore, the overlap of dysregulated genes in the pairwise combinations 
of MEF2D and either B or C gene sets was quite low (2 and 3 genes, respectively) in 
comparison to the extent of overlap seen in any of the other combinations, such as MEF2A 
and B (171 overlapping genes), MEF2A and C (110 genes), MEF2A and D (32 genes), and 
MEF2B and C (298 genes). Finally, there were only 21 out of over 7,000 dysregulated 
genes (<0.003%) shared by all four MEF2 knockdowns. These results suggest that only a 
small fraction of MEF2-dependent genes in C2C12 cells can be regulated by all four MEF2 
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proteins, but most can be regulated by two or three of these transcription factors, either as 
homodimers or combinations of heterodimers. 
Analysis of the dysregulated patterns, i.e., up- or down-regulated in all MEF2 gene 
sets, of the 21 genes revealed that only 5 out of the potential twenty-four different patterns 
were represented (Fig. 3.9). Interestingly, genes which were downregulated upon depletion 
of MEF2A or MEF2D were upregulated in MEF2B- or MEF2C-depletion and were the 
most prevalent group, comprising two-thirds of the dysregulated patterns. Additionally, 
only a single gene, Dyp19l1 (dumpy19-like 1), was downregulated in each of the MEF2 
isoform depletions. Dpy19l1 is the apparent ortholog of a C. elegans gene that encodes a 
transmembrane protein with glucosyltransferase activity (Buettner et al., 2013). Dpy19l1 
appears to function upstream of genes involved in muscle development in worms making 
it an exciting MEF2-dependent gene to further investigate. 
3.6 Classification of cellular processes in MEF2 knockdown gene sets  
To gain insight into the distinct roles of the MEF2 family in C2C12 myotubes, non-
overlapping dysregulated genes in each subgroup were categorized into cellular processes 
using three independent functional pathway analysis algorithms: Ingenuity Pathway 
Analysis (IPA), Gene Ontology (GO), and KEGG. 
IPA of MEF2-sensitive gene sets revealed that the preferentially dysregulated target 
genes from each MEF2 knockdown function in vastly different cellular processes (Table 
3.1). Many genes distinctly sensitive to MEF2A play roles in calcium signaling and actin 
cytoskeletal rearrangement. Genes preferentially regulated by MEF2B are associated with 
hepatic fibrotic pathways, ovarian cancer signaling, and human stem cell pluripotency. 
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Whereas, genes preferentially regulated by MEF2C are involved in control of the G1/S cell 
cycle checkpoint, eicosanoid signaling, and estrogen-mediated S-phase entry. Genes 
regulated by MEF2D appear to be involved in JAK2-like signaling and hypoxic response. 
Other canonical pathways in the MEF2D gene set such as atherosclerosis signaling and 
AMPK signaling did not reach statistical significance. Interestingly, IPA also revealed that 
some MEF2 family members regulate similar cellular processes even though the isoform-
sensitive genes do not overlap and code for different proteins. For example, the canonical 
pathways related to cancer was shared by MEF2A (molecular mechanisms of cancer) and 
MEF2C (ovarian cancer signaling), and Rho signaling was shared by MEF2A (Rho family 
GTPases) and MEF2D (RhoA signaling). These results likely reflect distinct proteins 
belonging to the same pathway. IPA was also performed on the 21 dysregulated genes 
common to all 4 MEF2 proteins (Table 3.1). Of the top 5 canonical pathways, three appear 
to be highly relevant to muscle function. Integrin and FAK signaling have been shown to 
play a role in adhesion and signaling at the myofiber periphery (Mayer, 2003), and calpain 
proteases are calcium-regulated proteases important in skeletal muscle homeostasis 
(Sorimachi and Ono, 2012). 
Like the IPA, both GO and KEGG algorithms revealed that the various MEF2-
isoform target genes function in different cellular processes and, in most instances, these 
algorithms predicted pathways similar to those predicted by IPA. It is worth noting that 
some overlap in basic skeletal gene programs is observed among the MEF2 family, 
particularly between MEF2A and C. Taken together, these computational analyses suggest 
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that the four mammalian MEF2 factors regulate partially overlapping but predominantly 
distinct gene programs in C2C12 differentiation. 
To mechanistically understand the preferential sensitivity of target genes to MEF2 
isoforms we reasoned that sensitivity to a given MEF2 protein is determined by minor 
variations in the MEF2 DNA binding site consensus sequence, with the assumption that a 
number of these genes are direct targets. Based on Find Individual Motif Occurances 
(FIMO) analysis of the proximal promoter regions no significant variations were observed 
in the consensus MEF2 DNA binding sequence, CTA(A/T)4TAG (data not shown). 
In the absence of any variations in MEF2 binding site sequence, we reasoned that 
the isoform-sensitivity of dysregulated genes in each MEF2 group results from a distinct 
combination of transcription factor (TF) binding sites in the various promoters. To identify 
TF motifs enriched in gene sets associated with a single MEF2 factor knockdown, we 
extracted the 5-kilobase region directly upstream of the putative transcriptional start site 
for each gene in a given set and performed de novo motif discovery using the MatInspector 
transcription factor binding site enrichment analysis (Genomatix). Motifs were considered 
significantly enriched in a set of promoters if the Z-score was greater than or equal to 2. 
As shown in Fig. 3.10A, over 90% of the overrepresented binding site motifs were shared 
by two or more MEF2 factors, and less than 10% of enriched motifs were found in genes 
regulated by a single MEF2 protein. De novo motifs were then sorted into groups based on 
their enrichment in gene sets associated with each of the four MEF2 isoforms. This analysis 
showed that 14% of MEF2A-, 1% of MEF2B-, 0% of MEF2C-, and 5% of MEF2D-
sensitive genes harbored motifs that were preferentially enriched in proximal promoter 
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regions in the respective MEF2 knockdown (Fig. 3.10B). Similar to the disparity in the 
number of dysregulated genes in each MEF2 knockdown, the number of de novo motifs 
associated with each MEF2 gene set varied greatly. As shown in Fig. 3.10B, a total of 15 
DNA binding site motifs were identified specifically in the MEF2A-sensitive gene set and 
were not shared by the other MEF2 isoform gene sets. This was followed by one distinct 
motif in the MEF2B- and 2 distinct motifs in the MEF2D-sensitive gene sets. Remarkably, 
the MEF2C-sensitive dysregulated genes did not harbor DNA binding site motifs specific 
to this data set. This analysis indicates that all of the de novo motifs in MEF2C-sensitive 
genes were found in one or more of the other MEF2-isoform gene sets. 
Another intriguing result of this analysis was the finding that not a single DNA 
binding sequence motif was preferentially associated with the overlapping genes from the 
MEF2B and C, MEF2B and D, and MEF2C and D sensitive promoter sets. All of the motifs 
found in these overlapping gene sets were also found in the MEF2A-sensitive gene set. 
Thus, there may be a common mechanism through which a subset of MEF2-dependent 
genes is regulated by the individual MEF2 proteins. 
Regardless of the MEF2-isoform sensitive gene set, most of the transcription 
factors predicted to bind to these DNA sequence motifs are broadly expressed and the 
majority encode C2H2 zinc fingers or homeodomains (Table 3.2). These particular binding 
domains are among the most prevalent in transcription factor superfamilies (Liu and 
Stormo, 2008; Messina et al., 2004; Svingen and Tonissen, 2006). Moreover, they can 
function both as activators and repressors, and regulate a broad spectrum of target genes 
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and cellular processes, including differentiation. Although these are large transcription 
factor families this analysis clearly identified specific transcription factors (Table 3.2). 
We next performed an extensive literature search to determine the cellular function 
of these predicted transcription factors (Table 3.2) and focus on those that were likely to 
play a role in skeletal muscle differentiation. Four of the TF binding sites enriched in the 
MEF2-sensitive gene sets bind factors that may play a role in skeletal muscle 
differentiation. In the MEF2A-sensitive module, the distal-less homeobox transcription 
factors Dlx1-6 were among the most significantly enriched TFs. Dlx factors are important 
for limb and craniofacial development. While few studies exist on their role in muscle 
development, a related family member, Msx1, is associated with maintenance of an 
undifferentiated state during migration of proliferative skeletal muscle precursors(Bendall 
and Abate-Shen, 2000). Another significantly enriched MEF2A-associated TF module 
identified Zfhx3/Abtf1, a well-characterized inhibitor of myogenic differentiation. It acts 
primarily as a transcriptional repressor through the obstruction of E-box motifs on muscle-
specific promoters. Although Zfhx3 functions as a repressor, one splice variant, Zfhx3-B, 
acts as a transcriptional activator that contributes to myogenic differentiation (Berry et al., 
2001; Heidt et al., 2007) . 
Two families of transcription factors were associated with MEF2D-sensitive genes 
in our de novo motif analysis. Meis1 and Pknox2 are members of a small family of 
transcription factors which function in skeletal muscle as pioneer transcription factors to 
stabilize the MyoD/E12 DNA interaction on sub-optimal E box sites, such as the E box 
found on the myogenin promoter (Grade et al., 2009; Heidt et al., 2007; Knoepfler et al., 
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1999). While little is known about the function of Pknox2, it is similar in homology to 
Meis1 and is highly expressed in skeletal muscle tissue (Imoto et al., 2001). 
The final transcription factor associated with MEF2D-sensitive genes is 
Gtf2ird1/Gtf3. Gtf3 shares high homology with TFII-1, suggesting an important role in the 
integration of muscle-specific transcription factor activity and the general transcriptional 
machinery of the cell (O'Mahoney et al., 1998). Gtf3 has 23 known splice variants, 11 of 
which are only detectable in skeletal muscle. Interestingly, the human Gtf3 ortholog is 
localized to a region of the genome that is deleted in Williams-Beuren syndrome, a disease 
associated with muscle weakness and atrophy.  Of the genes deleted in this region, Gtf3 is 
the only one associated with skeletal muscle function, suggesting an important role for Gtf3 
activity in human skeletal muscle (Tassabehji et al., 1999). 
The aforementioned transcription factors represent interesting candidates to further 
investigate the mechanisms of MEF2 isoform-specific transcriptional regulation. Although 
we highlighted transcription factors that may function in muscle, the computational 
analysis suggests that specificity in gene regulation by MEF2 isoforms is primarily 
established by unique combinations of broadly expressed transcription factors. The 
potential role of these transcription factors in muscle and their ability to mediate specificity 
to MEF2 isoform-dependent gene programs remains to be seen. 
3.7 Discussion  
The molecular mechanisms by which MEF2 controls gene expression and how its 
activity is regulated by signaling pathways in muscle have been intensely investigated. 
Previous studies have used dominant negative and genome wide chromatin 
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immunoprecipitation (ChIP) approaches to report the role of MEF2 in skeletal myoblast 
differentiation in vitro (Ornatsky et al., 1997; Paris et al., 2004; Wales et al., 2014). 
However, these studies did not explore potential differences in MEF2 isoforms, and a 
carefully designed systematic analysis into the distinct transcriptional functions of the 
individual vertebrate MEF2 proteins in this process has not been performed. Here, we have 
used acute isoform-specific knockdown of the four mammalian MEF2 proteins in a well-
defined muscle differentiation context followed by genome-wide expression profiling to 
examine the requirement of each MEF2 isoform and its downstream pathways in this 
process. 
Individual knockdown of mammalian MEF2 family members in C2C12 cells 
revealed three key findings. First,  MEF2A is absolutely required for C2C12 
differentiation, and the remaining MEF2 proteins, MEF2B, C, and D, are dispensable for 
this process. Second, there was a surprisingly broad spectrum in the number of genes 
sensitive to a given MEF2 isoform. Third, although depletion of MEF2B, C, or D either 
individually, in combination, or altogether did not cause an overt phenotype, we discovered 
that deficiency of individual MEF2 isoforms resulted in significant gene dysregulation. 
Interestingly, many of these genes did not overlap and were sensitive to a particular 
mammalian MEF2 isoform. 
Along these lines, our transcriptome results show varying degrees of overlap with 
previously published MEF2 chromatin immunoprecipitation (ChIP) studies. Using a 
custom CpG island array and a pan-MEF2 antibody twenty genes were identified in C2C12 
cells whose promoters were enriched for MEF2 binding (Blais et al., 2005). Of these, only 
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nine overlapped with our microarray data and were found exclusively in the MEF2A gene 
set suggesting these may be direct targets of MEF2A. Another study used a standardized 
microarray four days post-differentiation (C2C12 cells) to identify 22 genes enriched for 
MEF2 binding (Wales et al., 2014), of which 16 were significantly dysregulated in our 
study. These 16 genes were distributed among the MEF2 knockdown gene sets. A more 
recent study (Sebastian et al., 2013) looked at the binding enrichment of two MEF2D splice 
variants in C2C12 cells using ChIP-sequencing. These assays yielded 160 genes with 
significant MEF2D binding on differentiation day 5, and of these genes 126 are found in 
our MEF2 knockdown gene sets. Curiously, we found many of their “MEF2D-specific” 
genes to be sensitive to the knockdown of other MEF2 factors. These results suggest that 
genes bound by MEF2D may also be regulated by other MEF2 isoforms depending on 
context or are regulated by specific combinations of MEF2D heterodimers. Finally, an 
RNA-sequencing analysis of MEF2A siRNA knockdown in C2C12 myotubes (day 2) was 
performed (Wales et al., 2014). Of the 1207 dysregulated genes described in that study 
about 50% of the genes were found to overlap with our MEF2A dysregulated gene set. The 
relatively modest overlap of these gene sets may reflect the different time points, 
knockdown method, or procedure used to analyze gene expression profiles. 
Overexpression of MEF2C, MEF2D, or both in the MEF2A-deficient C2C12 
background was unable to rescue the impaired differentiation defect in these myoblasts. 
However, the MEF2-VP16 adenovirus was able to restore myotube formation and 
expression of MHC to wild-type levels. This difference may be explained by the ability of 
the MEF2-VP16 protein to function as a potent transcriptional activator and overcome any 
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encoded specificity within the regulatory regions of MEF2A-dependent genes. 
Additionally, because MEF2-VP16 contains the MEF2C-DNA binding domain, which is 
highly conserved among the mammalian MEF2 proteins and has only a single amino acid 
difference between this and the MEF2A DNA binding domain, these results suggest that 
target gene selectivity is directed by the carboxy-terminal transactivation domain of the 
MEF2 proteins. Therefore, an interesting area of investigation in the future would be to 
generate chimeric MEF2 proteins harboring different combinations of the DNA-binding 
and carboxy terminal domains to determine whether any of these MEF2 variants are 
capable of rescuing the differentiation defect or altering target gene preferences. 
Given the profound differentiation defect in MEF2A-deficient C2C12 cells we 
searched the MEF2A dysregulated gene set for genes that may help explain the phenotype. 
Although the MEF2A gene set has numerous dysregulated genes that may explain the 
phenotype, we were intrigued by four of these genes. The first gene that caught our 
attention was MyoD. MyoD is a master muscle regulatory transcription factor in myogenic 
differentiation, and among its myriad roles in muscle gene regulation its knockdown 
prevents myoblast differentiation (Megeney et al., 1996). We also noted the 
downregulation of myoferlin (Myof). Myoferlin is responsible for sarcolemmal repair at 
the site of myoblast fusion, and a deficiency prevents myoblast fusion (Doherty et al., 
2005). The final two gene candidates, Palld (palladin) and Fnbp1l (formin binding protein), 
are actin-associating remodeling molecules that play integral roles in actin-mediated 
signaling required for myogenic differentiation and myotube fusion (George et al., 2014; 
Nguyen et al., 2014). Loss of either of these proteins leads to a fusion-deficient phenotype 
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in C2C12 differentiation. While expression of none of these genes is completely abrogated 
in the MEF2A knockdown, the collective downregulation of these genes may contribute to 
defective C2C12 differentiation. 
The cellular pathways dependent on individual MEF2 isoforms in C2C12 
myoblasts varied considerably, which is not surprising given the extent of non-overlapping 
genes. MEF2A was predicted to regulate genes involved in actin cytoskeletal 
rearrangement, consistent with its regulation of structural genes encoding proteins 
localized to the costamere in cardiac muscle (Estrella and Naya, 2014; Ewen et al., 2011).  
It is intriguing that regulation of the actin cytoskeleton was not identified among the top 
canonical pathways in the MEF2B, C, or D dysregulated gene sets considering these MEF2 
proteins have been shown to regulate muscle structural genes in vitro and in vivo (Estrella 
and Naya, 2014). Although expression profiling clearly identified this category of genes in 
all of the MEF2 knockdowns, other pathways were more significantly dysregulated in the 
MEF2B, C, or D gene sets. Based on the extensive overlap of the MEF2B, C, and D 
dysregulated genes, it appears that regulation of muscle structural genes can be 
compensated for by any one of the remaining MEF2 proteins and/or that regulation of these 
genes is more dependent on MEF2A. Given the importance of cytoskeletal proteins in 
muscle function it is possible that these genes have evolved less stringent transcriptional 
mechanisms as it relates to their regulation by the various MEF2 isoforms. 
The computational analysis of predicted MEF2 binding sites in each of the MEF2-
sensitive dysregulated gene sets did not identify any significant differences in this 
consensus sequence. This is not entirely surprising since the binding to different MEF2 
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consensus sequences in an isoform-specific manner has not been reported. One caveat of 
using FIMO to identify MEF2 cis-acting sequences is that this algorithm is based 
exclusively on published MEF2 binding sites, thereby restricting the MEF2 motif analysis 
to this limited data set. Nevertheless, the computational analysis revealed a significant 
difference in the transcription factor modules of overrepresented DNA binding sites 
associated with each of the various MEF2-isoform gene sets. An interesting finding that 
emerged in this analysis is the observation that not a single, predicted transcription factor 
binding site motif was uniquely associated with the MEF2C-sensitive cohort. This likely 
resulted from complete overlap with analogous motifs found in the other MEF2-isoform 
regulated genes. These findings suggest that mechanisms beyond distinct co-regulators in 
the proximal promoter are necessary for MEF2C-dependent gene regulation in skeletal 
muscle. Perhaps transcription of MEF2C-sensitive genes by MEF2C requires a specific 
arrangement of common DNA binding site motifs rather than unique sequences in these 
regulatory regions. 
Another intriguing finding was the lack of E-box motifs, which are recognized by 
basic helix-loop-helix proteins such as MyoD. It is firmly established that MEF2 and the 
MyoD family form an important cooperative interaction in the regulation of muscle genes 
(Molkentin and Olson, 1996). In our computational analysis E-box motifs were actually 
found to be significantly underrepresented. Our interpretation of this result is that E-box 
motifs are prevalent throughout the mouse genome (Cao et al., 2010), and consequently, 
using proximal promoters as the background from which motifs are subtracted results in 
significantly reduced frequency of this binding site in the MEF2-sensitive gene sets. 
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Our findings reveal isoform-specific differences in the regulation of genes by the 
mammalian MEF2 transcription factors in C2C12 differentiation. It is important to note, 
although C2C12 myoblasts are a widely accepted in vitro model of skeletal muscle 
differentiation, the MEF2-dependent transcriptome in these cells may differ from that in 
primary skeletal myoblasts. Additionally, our computational data support the model 
whereby MEF2-dependent transcriptional regulation is modulated by co-factor interactions 
and not through differences in the MEF2 consensus sequence. The present study has taken 
this notion a step further by demonstrating that the target gene selectivity of a given MEF2-
isoform may be dictated by one or more distinct co-regulatory partners. Our results pave 
the way for future studies of MEF2-dependent regulation of isoform-sensitive genes in 
muscle by focusing on the in vivo occupancy of specific dimeric combinations of MEF2 
proteins in the context of chromatin. 
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FIGURE 3.1. Robust and specific knockdown of MEF2B protein using an shRNA 
adenovirus. A and D, schematic representations of Mef2b (A) and Mef2d (D) transcripts. 
shRNA adenoviruses were generated to target the carboxyl-terminal region of the Mef2 
transcripts (black bar) for knockdown in C2C12 myoblasts. The target sequences excluded 
regions containing alternatively spliced exons and were selected based on homology 
between mouse, human, and rat Mef2b or Mef2d sequences. B and E, Western blot analysis 
of shMef2b (B) and shMef2d (E) specificity against overexpressed MEF2 constructs in 
COS cells. Extracts for shMef2b knockdown of MEF2B-FLAG Western blot were cropped 
for image clarity (B, upper panel) but analyzed on the same gel (B, lower panel). shMef2b 
195 (sequence shown in A) was used to generate adenovirus. C and F, quantitative RT 
analysis of endogenous Mef2b (C) and Mef2d (F) knockdown in C2C12 myotubes at 
differentiation day 3. The data are means ±S.E. *, p < 0.05; ****, p <0.0001.  
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FIGURE 3.2. shRNA-mediated knockdown of MEF2 proteins in C2C12 myoblasts. 
C2C12 myoblasts were transduced with adenoviruses harboring shRNAs targeting Mef2a, 
-b, -c, or -d, or with an shRNA against lacZ as a negative control. A–C, knockdown of 
Mef2a (A), but not Mef2b, -c, or -d, resulted in impaired myotube formation and 
differentiation as shown by Western blot analysis of the muscle-specific marker myosin 
heavy chain (MHC) (B and C). The data are means ± S.E. **, p < 0.01; ***, p < 0.001. 
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FIGURE 3.3. Combinatorial knockdown of MEF2 proteins in C2C12 myoblasts. A, 
combinatorial knockdown of Mef2a/b, Mef2a/c, and Mef2a/d failed to modulate the 
differentiation defect observed in the Mef2a knockdown alone. Additionally, simultaneous 
knockdown of Mef2b/c, Mef2b/d, Mef2c/d, and Mef2b/c/d failed to produce any overt 
morphological defects in C2C12 differentiation. Western blot analysis of myosin heavy 
chain (B) and accompanying densitometry (C) for the combinatorial knockdowns show 
that differentiation is only affected in MEF2A depleted cells. The data are means ± S.E. 
**, p < 0.01; ***, p < 0.001.  
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FIGURE 3.4. Overexpression of MEF2 in C2C12 myoblasts. A, Western blot analyses 
of C2C12 cells transduced with MEF2 isoform adenoviruses confirm an increase in MEF2 
protein levels, relative to the β-gal control. OE, overexpression. B, overexpression of 
MEF2A, -C, or -D did not overtly modulate C2C12 myotube formation. Interestingly, 
overexpression of the MEF2D muscle-specific isoform did not result in enhanced myotube 
formation, as previously described (Sebastian et al., 2013).  
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FIGURE 3.5. Rescue of MEF2 in C2C12 myoblasts. A, overexpression of MEF2-VP16, 
but not overexpression of MEF2C or -D alone or in combination, was able to rescue the 
differentiation defect observed in MEF2A depleted C2C12 myotubes. B, Western blot 
analysis of myosin heavy chain (MHC) expression demonstrates overexpression of MEF2-
VP16, but not MEF2C or -D alone or in combination, was able to rescue impaired 
differentiation in MEF2A deficient cells. C, quantification of the myosin heavy chain 
expression Western blot analysis. The data are means ± S.E. **, p < 0.01; ***, p < 0.001. 
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FIGURE 3.6. MEF2A overexpression is knocked down by shMef2a. Overexpression of 
MEF2A was unable to restore MEF2A to wild type levels (A), because the MEF2A cDNA 
encoded in this adenovirus is knocked down by shMef2a. B, quantification of MEF2A 
Western blot analysis from a single experiment. 
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FIGURE 3.7. Comparative analysis of MEF2 knockdown gene sets. Microarray analysis 
reveals that C2C12 cells are differentially sensitive to depletion of the four MEF2 isoforms. 
A, summary of total significantly dysregulated (q < 0.05) genes in each MEF2 isoform 
shRNA knockdown. B, a composite Venn diagram incorporating all overlapping gene sets 
as determined by the Tukey’s honest significant difference post hoc test (q < 0.05).  
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FIGURE 3.8. Microarray validation. Quantitative RT-PCR analysis of a subset of genes 
dysregulated in the Mef2 knockdown microarrays. Cdkn1c, cyclin-dependent kinase 
inhibitor 1c; Sept4, septin 4; Hspb7, heat shock protein family member 7; Myom1, 
myomesin 1; Stc2, stanniocalcin 2; Tex16, testis expressed gene 16; Selp, selectin, 
platelet; C1ql1, compliment component 1, q subcomponent-like 1; Bace2, beta-site app-
cleaving enzyme 2; Pi16, peptidase inhibitor 16; Themis, thymocyte selection associated; 
Glipr1, GLI pathogenesisrelated 1 (glioma); Cpa4, carboxypeptidase a4; Fam78a, family 
with sequence similarity 78; Ppp1r3a, protein phosphatase 1, regulatory (inhibitor) 
subunit 3a.  The primer sequences are listed under “Table 2.1” The data are means ± S.E. 
*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., not significant 
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FIGURE 3.9. Gene regulation patterns of gene sets sensitive to the loss of all four 
MEF2 proteins. Only five of the possible patterns of dysregulation are represented in the 
commonly dysregulated gene set. Of these patterns, the most prevalent group (66%) were 
genes that were down-regulated in MEF2A or MEF2D depletion and up-regulated in 
MEF2B or MEF2C depletion. Additionally, only a single gene, Dpy19l1 (DumPY19-like 
1), was dysregulated in the same direction upon individual knockdown of each MEF2 
factor.  
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FIGURE 3.10. Identification of distinct TF-binding sites associated with each MEF2 
knockdown gene set. A, transcription factor-binding motif enrichment analysis was 
performed on the proximal promoter regions of each MEF2 gene set. Approximately 43% 
of binding motifs were shared by all four gene sets, 32% were shared by three MEF2 gene 
sets, 18% were shared by two MEF2 gene sets, and 7% are enriched only in genes regulated 
by a single MEF2 factor. B, breakdown of motif distribution by MEF2 isoform. MEF2A 
had the highest percentage of uniquely enriched motifs, and no unique motifs were 
identified for MEF2C-sensitive genes. TFBS, transcription factor binding site. 
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TABLE 3.1. Analysis of canonical pathways associated with each MEF2 isoform 
Each preferentially sensitive MEF2 gene set, including the 21 commonly dysregulated 
genes, were analyzed using Ingenuity Pathway Analysis software. The top five most 
significantly regulated canonical pathways are provided. These pathways were analyzed 
for statistically significant association with each unique MEF2-sensitive gene set, and all 
were found to be significant (p < 0.05 chance occurrence) with the exception of the 
MEF2D-associated canonical pathways, likely because of the small number of MEF2D-
sensitive genes dysregulated in the expression analysis. Also provided is the amount of 
genes dysregulated in each MEF2 factor knockdown in relation to the accepted number of 
genes associated with each canonical pathway (ratio). 
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Canonical Pathway p-value Ratio
MEF2A
Molecular Mechansisms of Cancer 2.40E-08 92/387 (0.238)
Calcium Signaling 2.26E-07 55/217 (0.253)
Germ Cell-Sertoli Cell Junction Signaling 6.20E-06 46/169 (0.272)
Actin Cytoskeletal Signaling 1.63E-05 57/242 (0.236)
Signaling by Rho Family GTPases 1.96E-05 60/262 (0.229)
MEF2B
Hepatic Fibrosis/Hepatic Stellate Cell Activation 1.31E-03 5/155 (0.032)
Ovarian Cancer Signaling 7.57E-03 4/152 (0.026)
Human Embryonic Stem Cell Pluripotency 7.77E-03 4/161 (0.025)
Ceramide Signaling 1.13E-02 3/91 (0.033)
Apoptosis Signaling 1.47E-02 3/100 (0.03)
MEF2C
Cell Cycle: G1/S Checkpoint Regulation 3.14E-03 3/68 (0.044)
Eicosanoid Signaling 3.14E-03 3/85 (0.035)
Molecular Mechanisms of Cancer 5.49E-03 6/387 (0.016)
Estrogen-mediated S-phase Entry 5.48E-03 2/28 (0.071)
Sulfate Activation for Sulfonation 9.42E-03 1/8 (0.125)
MEF2D
Role of JAK2 in Hormone-like Cytokine Signaling 4.03E-02 1/37 (0.027)
Hypoxia Signaling in the Cardiovascular System 7.69E-02 1/68 (0.015)
RhoA Signaling 1.32E-01 1/122 (0.008)
Artherosclerosis Signaling 1.37E-01 1/138 (0.007)
AMPK Signaling 1.50E-01 1/180
All MEF2
Regulation of Cellular Mechanics by Calpain Protease 3.20E-05 3/73 (0.041)
nNOS Signaling in Neurons 1.20E-03 2/52 (0.038)
Integrin Signaling 1.24E-03 3/208 (0.014)
Amyloid Processing 1.41E-03 2/61 (0.033)
FAK Signaling 4.05E-03 2/106 (0.019)
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TABLE 3.2. Transcription factor-binding site enrichment analysis. Binding site 
enrichment analysis was performed on gene sets preferentially regulated by each MEF2 
factor using the Genomatix software suite. Fifteen motifs were uniquely enriched in the 
MEF2A-sensitive gene set, two were enriched in the MEF2B set, no motifs were enriched 
in the MEF2C set, and two were enriched in the MEF2D set. The table provides the 
description of each enriched motif with a calculated Z score (Z > 2 was considered 
significantly enriched). The known binding factors and their relevant binding domains are 
included. Finally, a summary of the function of each of these binding factors is provided. 
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TF Module Module Description Z-Score Known Factor Binding Domain Function
Mef2a
V$SF1F Vertebrate steroidogenic factor 13.53 Nr5a1 C4 zinc finger domain Essential for embryonic sex determination
V$DLXF Distal-less homeodomain 
transcription factors
12.93 Dlx1 through 6 homeodomain Repressor, important of embryonic
 development (shared function)
V$IKZF Ikaros family zinc finger 5 10.16 Ikzf5 C2H2 zinc finger domain Repressor, lymphocyte development
V$BARB Barbiturate-inducible element box 9.68 Not characterized Not characterized
V$ZF05 C2H2 zinc finger transcription factor 5 9.49 Zfp410 C2H2 zinc finger domain ECM remodeling
V$IKRS Ikaros zinc finger family 8.8 Ikzf1 through 4 C2H2 zinc finger domain Repressor, lymphocyte development (shared 
function)
V$THAP THAP domain containing protein 6.72 Thap1 THAP domain Cell cycle progression dow nstream of Rb-
E2F signaling
V$HEAT Heat shock factors 6.34 Hsf1, Hsf2, Hsf4 HSF-HTH Heat-sensitive activator, embryonic 
development
V$ATBF AT-binding transcription factor 6.15 Zfhx3 C2H2 zinc finger domain, 
C2HC zinc finger domain, 
homeodomain
Repressor, promotes neuronal and myogenic 
differentiation
V$OVOL OVO homolog-like transcription factor 6.15 Ovol1, Ovol2 C2H2 zinc finger domain Ovol1: repressor, contributes to epithelial 
development. 
Ovol2: repressor, embryonic cardiovascular V$GTBX GT box 4.38 Zfp628 C2H2 zinc finger domain Uncharacterized transcriptional regul tor
V$PTF1 Pancreas transcription factor 1, 
heterotrimeric transcription factor
4.33 Ptf1a, Rbpj, Rbpjl bHLH Ptf1a: involved in pancreatic and neuronal 
development. 
Rbpj: involved in cardiac and hematopoeitic 
development. 
Rbpjl: uncharacterized transcriptional 
regulator.
V$RU49 Zinc finger transcription factor RU49, 
zinc finger proliferation 1 - Zipro1
3.4 Zscan21 C2H2 zinc finger 
domain
Uncharacterized transcriptional regulator
V$HZIP Homeodomain-leucine zipper 
transcription factors
2.21 Homez homeodomain Uncharacterized transcriptional regulator
V$CHOP C/EBP homologous protein (CHOP) 2.12 Ddit3 bZIP Stress sensitive transcriptional regulator, 
negative regulator of myogenic dif ferentiation.
Mef2b
V$BTBF BTB/POZ (broad complex, TramTrack, 
Bric-a-brac/pox viruses and zinc f ingers)
2.56 Zbtb33 BTB-POZ C2H2 
zinc fingers
Repressor of Wnt target genes. 
Activator of an unrelated set of genes.
Mef2c
Mef2d
V$TALE TALE homeodomain class 
recognizing TG motifs
3.94 Meis1, Meis2, Meis3, 
Pknox1,Pknox2, 
Tgif1, Tgif2
TALE class 
homeodomain
Meis1: angiogenic and hematopoeitic 
development. 
Meis2: mammalian eye/neuronal development. 
Meis3: activator, dow nstream of PKB 
signaling. 
Pknox1: activator, hematopoeitic and 
angiogenic development. 
Pknox2: associated w ith actin cytoskeleton.
Tgif1: Dow nstream of TGF-β signaling, 
embryonic development. 
Tgif2: uncharacterized regulator dow nstream 
of TGF-β signaling.
V$DICE Dow nstream Immunoglobulin 
Control Element, critical for B cell 
activity and specificity
2.31 Gtf2i, Gtf2ird1 GTF2I repeat domain Gtf2i: embryonic development, negative 
regulator of  angiogenesis. 
Gtf2ird1: modulates cell cycle progression, 
skeletal muscle differentiation.
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Chapter 4: MEF2D sustains cardiomyocyte cell cycle arrest through transcriptional 
regulation of PTEN 
4.1 Introduction 
Numerous cardiac diseases are associated with damaged cardiac muscle, which 
does not have the ability to regenerate. Mammalian cardiomyocytes are largely incapable 
of re-entering the cell cycle once they have terminally differentiated. Understanding the 
mechanisms governing cardiomyocyte cell cycle control is the first step in developing 
therapies to regenerate damaged cardiac muscle. MEF2 is an evolutionarily conserved 
family of transcription factors that plays a central role in cardiovascular development. 
There is also substantial evidence that implicates MEF2 as a downstream effector in models 
of cardiac dysfunction. One of the MEF2 family members, MEF2D, performs an important 
function in cardiac remodeling in response to stress. However, the specific cellular 
pathways regulated by MEF2D in cardiac myocytes are largely unknown. To gain a better 
understanding of the gene programs MEF2D is regulating in the heart, we used RNA 
interference to knock down MEF2D in primary neonatal cardiomyocytes followed by 
global gene expression profiling. Using this microarray approach along with pathway 
prediction analysis we have discovered a role for MEF2D in cardiomyocyte cell cycle 
regulation. A number of genes encoding cell cycle regulators were found to be dysregulated 
in MEF2D-deficient cardiomyocytes. Their dysregulation was subsequently validated at 
the RNA and protein level with real-time PCR and Western blot analyses, respectively. We 
show that MEF2D-deficient cardiomyocytes up-regulate a subset of positive cell cycle 
regulators such as PCNA and cyclins D1 and D3, while also down-regulating a subset of 
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cell cycle inhibitors. Moreover, we show that PTEN, a negative regulator of the AKT/PKB 
pathway is depleted in MEF2D-deficient cardiomyocytes resulting in AKT activation. This 
newly uncovered role for MEF2D in cell cycle control suggests that MEF2D is a key 
regulator in directing cell cycle exit and terminal differentiation of proliferating 
cardiomyocytes. A better understanding of the mechanisms by which MEF2D regulates 
cell cycle gene programs could lead to the development of therapies that promote 
cardiomyocyte cell cycle re-entry as a means to replace injured cardiomyocytes in diseased 
hearts, and thus have a major impact on cardiovascular health. 
4.2 Loss of MEF2D in cardiomyocytes perturbs the cell cycle 
We have previously described specific and robust knockdown of MEF2D in C2C12 
myoblasts using an shRNA adenovirus (Fig.3.1). Efficacy of endogenous MEF2D 
knockdown was tested in neonatal rat ventricular myocytes (NRVMs). qRT-PCR and 
Western blot analysis demonstrate a significant reduction of endogenous MEF2D protein 
levels in NRVMs three days after transduction (Fig. 4.1A-C).  
To gain a better understanding of the gene programs MEF2D regulates in cardiac 
muscle, RNA interference was used to knock down MEF2D in primary neonatal 
cardiomyocytes, followed by global gene expression profiling. NRVMs were transduced 
with either shMef2d or the shlacZ negative control, and cells were harvested for RNA 72 
hours later. The RNA preparations were then compared using an Affymetrix Gene Chip 
Rat Gene 1.0ST array. Knock down of MEF2D in neonatal cardiomyocytes resulted in 
dysregulation of 279 genes by 1.5 fold or more. Of the 279 dysregulated genes, 159 were 
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downregulated and 120 were upregulated by at least 1.5 fold. Surprisingly, Ingenuity 
Pathway Analysis® of these 279 genes revealed a significant association between MEF2D 
and the cell cycle, DNA replication, recombination, and repair with p values < 0.05 (Table 
4.1). Furthermore, IPA® identified the cell cycle as the top dysregulated canonical pathway 
in MEF2D-deficient NRVMs (Table 4.2). Of the 31 genes associated with cell cycle control 
of chromosomal replication, five were upregulated in the absence of MEF2D (Table 4.2). 
KEGG pathway analysis corroborated results obtained with IPA®. KEGG analysis 
predicted a total of four perturbed canonical pathways in the MEF2D knockdown gene set, 
with the top dysregulated pathway being the cell cycle (Table 4.3). Interestingly, the cell 
cycle was the only canonical pathway to be significantly associated with MEF2D with a p 
value of less than 0.05. It is important to note that both IPA® and KEGG software compare 
gene sets against defined pathways, ignoring atypical functions or roles of the input gene 
set.  
 Next, the microarray data were analyzed for dysregulation of cell cycle associated 
genes. Of the 279 genes dysregulated by at least 1.5 fold, 12 had roles in the cell cycle 
(Table 4.4). With the exception of PTEN, the dysregulated cell cycle-associated genes act 
primarily as positive regulators. Several positive cell cycle regulators, including Cdt1, 
cyclin E1 (Ccne1), cyclin E2 (Ccne2), Cdc6, Mcm3, Mcm5, and Mcm6 were upregulated 
in MEF2D-depleted cardiomyocytes. Furthermore, two genes necessary for the spindle 
assembly checkpoint in mitosis, Ttk and Bub1, were downregulated in the absence of 
MEF2D. Interestingly, phosphatase and tensin homolog (Pten) was downregulated by 1.6 
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fold on the microarray (Table 4.4). PTEN is an important negative regulator of the 
PI3K/AKT/PKB pathways which promotes cell cycle progression and cell survival. 
4.3  Loss of MEF2D results in activation of the cell cycle  
Quantitative reverse transcription real-time PCR (qRT-PCR) was used to validate 
dysregulation of cell cycle gene expression as observed on the microarray. A large subset 
of the genes perturbed on the microarray were significantly upregulated at the transcript 
level. Among those genes showing a significant increase in transcript levels were the 
positive cell cycle genes Mcm3, Mcm5, Mcm6, cyclin E1 (Ccne1) and cyclin E2 (Ccne2) 
(Fig.4.2). Proliferating cell nuclear antigen (PCNA) interacts with MCM3, -5, and -6 at the 
replication fork and is necessary for DNA replication. Therefore, even though it did not 
meet the 1.5 fold dysregulation cut-off we examined Pcna mRNA expression and found 
that it was significantly upregulated by 2.5-fold in MEF2D-depleted cardiomyocytes (Fig. 
4.2).   
To investigate transcriptional pathways and the associated transcription factors that 
could be responsible for the up-regulation of these cell cycle genes, binding site enrichment 
analysis was performed on the six validated upregulated cell cycle genes using the 
Genomatix software suite. We examined the promoter regions encompassing five kilobases 
upstream of the transcriptional start sites of Pcna, Mcm3, Mcm5, Mcm6, Ccne1, and Ccne2. 
Eleven motifs were enriched with a calculated Z score greater than 2 (Table 4.5). HOX and 
FOX transcription factors were among the list of factors known to bind motifs enriched in 
the promoters of the genes examined. Curiously, E2F binding motifs were not enriched in 
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the promoters of the genes examined, despite their established roles as transcriptional 
activators of a subset of Mcm3, Mcm5, and Mcm6.  
To corroborate transcript expression data and determine whether cell cycle 
components were being upregulated at the protein level, we examined protein expression 
of several positive cell cycle regulators. Cyclin D1, cyclin D3, CDK2, and PCNA levels 
were increased in MEF2D depleted cardiomyocytes, when compared to the shlacZ negative 
control (Fig. 4.3A, B).  Cyclin E interacts with CDK2 to allow cells to progress from G1 to 
S phase of the cell cycle. Additionally, cyclin D complexes with CDK4 and -6 to allow 
transition from G1 to S phase. One notable substrate of the cyclin D/CDK4 and -6 complex 
is the retinoblastoma tumor suppressor protein (pRb). pRb inhibits cell cycle progression 
by suppressing E2F transcriptional activity. Cyclin D/CDK4 promotes cell cycle 
progression by phosphorylating and inactivating pRb, thereby allowing cells to progress 
through the cell cycle. Taken together, these data suggest that cyclins and CDKs are being 
upregulated to allow cell cycle progression.  
Moreover, we examined transcript expression of the CIP/KIP and INK families of 
cell cycle inhibitors. With the exception of p21 (Cdkn1a) and p57 (Cdkn1c), cell cycle 
inhibitor transcript levels are largely unperturbed in MEF2D-deficient cardiomyocytes 
(Fig.4.4). The genes encoding p21 and p57 are FOXO transcriptional targets, and prevent 
cells from progressing through the cell cycle. It is paradoxical that we see an increase in 
gene expression for two opposing pathways. However, the cell cycle is tightly controlled 
and multiple pathways are required for its full activation.  
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4.4  PTEN is a direct target of MEF2D 
PTEN is a tumor suppressor that indirectly inhibits AKT/PKB activation by 
antagonizing PI3K mediated conversion of PIP2 to PIP3 (Crackower et al., 2002; Hamada 
et al., 2005; Oudit et al., 2004; Wishart and Dixon, 2002). Mutations in the PTEN gene are 
present in a large number of cancers and PTEN is implicated in the progression of heart 
failure and the associated maladaptive cardiac remodeling (Lutucuta et al., 2004; Oudit et 
al., 2008). Curiously, the PTEN knockout phenotype closely mimics the MEF2D knockout 
mouse model which also displays resistance to cardiac remodeling in response to stress, 
possibly implicating both PTEN and MEF2D in the same pathway (Kim et al., 2008; Oudit 
et al., 2008).  
Microarray analysis revealed a 1.6-fold reduction of Pten mRNA in MEF2D 
depleted cardiomyocytes. qRT-PCR and Western blot analysis confirmed this 
dysregulation showing a 2.5-fold reduction in PTEN transcript (Fig. 4.5A) and protein 
levels (Fig. 4.5B, C) when compared to the negative control. 
Examination of the Pten upstream regulatory region revealed several A/T rich 
sequences within 5 kb upstream of the Pten transcriptional start site. We identified one 
evolutionarily conserved MEF2 binding site with high similarity to the MEF2 consensus 
sequence approximately 4600 bp upstream of the putative Pten transcriptional start site 
(Fig. 4.6A). This newly identified MEF2 site and its flanking sequences shared high 
conservation among human, mouse, rat, cow, and pig, suggesting that MEF2D 
transcriptionally regulates Pten. To determine whether MEF2D could transcriptionally 
activate the newly identified MEF2 binding site, rat genomic DNA was used to generate 
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expression constructs. The rat genomic sequence was used for consistency, since our 
characterization of MEF2D function in cardiomyocytes is being performed in neonatal rat 
cardiomyocytes. A 500 base-pair region containing the conserved MEF2 sites was cloned 
into a promoter-containing luciferase expression construct (pGL3promoter -4596 MEF2) 
and subsequently used in reporter assays. As a negative control, the core MEF2 binding 
site was mutated to prevent MEF2 binding (Fig. 4.6B). MEF2D overexpression in 
HEK293T cells was able to induce a 1.8-fold increase in activity of the Pten upstream 
regulatory region containing the newly identified Mef2 binding site (Fig. 4.7). In a 
complementary experiment, an electrophoretic mobility shift (EMSA) was performed 
using in vitro translated MEF2D and nuclear extracts from cardiomyocytes. The EMSA 
demonstrated that MEF2D was able to bind the MEF2 sites identified within the Pten 
upstream regulatory region, and binding was severely diminished when the core A/T 
sequence within the MEF2 binding site was mutated (Fig.4.8). Furthermore, an antibody 
specific for MEF2D super-shifted the band, demonstrating that the indicated shift was a 
MEF2D/Pten upstream regulatory region fragment complex (Fig.4.8).    
4.5  MEF2D negatively modulates the cell cycle through AKT signaling 
The PI3K-AKT/PKB signaling pathway has a critical role in cell cycle progression 
and cell survival (Cantley, 2002; Oudit et al., 2004). AKT/PKB is tightly regulated in the 
cell, and promotes cardioprotection in mice subjected to cardiac injury (Fujio et al., 2000; 
Matsui et al., 1999; Matsui et al., 2001). PTEN antagonizes PI3K activity to indirectly 
inhibit AKT activation in the heart (Crackower et al., 2002; Hamada et al., 2005; Oudit et 
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al., 2004; Wishart and Dixon, 2002), and loss of PTEN activity result in aberrant AKT/PKB 
activation. Interestingly, chronic AKT activation in the heart results in impaired recovery, 
increased injury, and heart failure in mice subjected to ischemia/reperfusion injury 
(Nagoshi et al., 2005).  
MEF2D-depleted cardiomyocytes display a decrease in PTEN expression. It 
therefore stands to reason that we should see an increase in AKT phosphorylation and 
activation in these cells. Western blot analysis confirms that MEF2D-depleted 
cardiomyocytes exhibit an increase in phospho-AKT at S473 and T308 demonstrating 
activation of the AKT/PKB pathway (Fig.4.9). Importantly, there is no appreciable change 
in total AKT levels, indicating that the increase in phosphorylated AKT is due to the loss 
of PTEN activity, and not changes in AKT protein levels overall. These results are 
consistent with the increase in cell cycle gene expression we observe in MEF2D depleted 
cardiomyocytes is a direct result of AKT activation.  
4.6  FOXO3a is enriched in the cytoplasm of MEF2D depleted NRVMs 
Forkhead box O (FOXO) transcription factors are downstream targets of AKT with 
established roles in cardiac growth, cell cycle regulation, and cell death (Skurk et al., 2005; 
Terragni et al., 2011). FOXO promotes cell cycle exit by promoting activation of p27 and 
p130, two cell cycle inhibitors (Liang and Slingerland, 2003). Phosphorylation by AKT 
causes FOXO to be excluded from the nucleus, thus preventing FOXO transcriptional 
activity and allowing cell cycle progression to proceed.  
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Given that FOXO is a substrate of AKT that inhibits the cell cycle, we determined 
whether FOXO was indirectly mediating the increase of positive cell cycle genes observed 
in MEF2D deficient cardiomyocytes. Because FOXO3a has established roles in the heart, 
and regulates cardiomyocyte size downstream of AKT (Skurk et al., 2005) we focused our 
analysis specifically on this factor. Immunocytochemistry probing for FOXO3a revealed 
that MEF2D deficient cardiomyocytes had increased levels of cytoplasmic FOXO3a when 
compared to the control (Fig. 4.10A, B). These findings suggest that MEF2D depletion 
results in FOXO3a nuclear extrusion and inactivation, resulting in cell cycle activation.  
4.7 Inhibition of PI3K/AKT blunts activation of cell cycle genes 
PI3K promotes AKT activation in response to growth stimuli, ultimately resulting 
in cell proliferation and survival To determine whether the increase of positive cell cycle 
regulatory genes observed in MEF2D deficient cardiomyocytes was a result of AKT 
activation, we treated MEF2D-deficient NRVMs with GDC-0941 (Selleck USA), a potent 
PI3K inhibitor (Shi et al., 2014). PI3K inhibition ablated the upregulation of Mcm5, Pcna, 
Ccne1, and Ccne2 in MEF2D-deficient cardiomyocytes (Fig. 4.11). While addition of 
GDC-0941 did not abolish up-regulation of Mcm3 or Mcm6, the increase in transcript 
levels was blunted nearly 2-fold in comparison to MEF2D knockdown alone (Fig. 4.11). 
This discrepancy is likely due in part to dosage of the pharmacological inhibitor GDC-
0941. As expected, down-regulation of Pten, which acts antagonistically to PI3K to prevent 
AKT activation, was unaffected at the transcript level by the addition of GDC-0941 to 
MEF2D-deficient cardiomyocytes (Fig. 4.12).  
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Finally, given the striking up-regulation of positive cell cycle markers we were 
interested in determining whether MEF2D-depleted cardiomyocytes were actually 
proliferating. To that end, we performed immunocytochemistry on MEF2D-depleted 
NRVMs with Ki67, a well-defined marker expressed in the active phases of the cell cycle. 
Cardiomyocytes were distinguished from cardiac fibroblasts with α-actinin, a muscle 
specific marker.  Surprisingly, MEF2D-depleted NRVMs did not show increased levels of 
Ki67 expression (Fig. 4.13 A, B). Furthermore, MEF2D depleted NRVMs did not have 
increased cardiomyocyte numbers when compared to the negative control (Fig. 4.13C). 
Given this unexpected result, we performed an EdU incorporation assay, a more sensitive 
method of measuring cell proliferation. We failed to see a difference in EdU-positive cells 
between the MEF2D knockdown and lacZ control, indicating that replication was not 
occurring in MEF2D-depleted cells. These results were surprising given that the molecular 
characterization of MEF2D-depleted NRVMs suggested cell cycle activation. 
4.8 Discussion  
 MEF2 is an evolutionarily conserved transcription factor family that plays a central 
role in cardiovascular development and differentiation. In addition to the cardiac defects 
observed in MEF2 knockout models, there is substantial evidence that implicates MEF2 as 
a downstream effector in models of cardiac dysfunction. Here, we discovered a role for 
MEF2D in cardiomyocyte cell cycle regulation. We functionally characterized the role of 
MEF2D in cardiomyocytes using microarray technology and bioinformatics tools for 
analysis. To our surprise, IPA® and KEGG analysis both predicted a significant 
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association between MEF2D and cell cycle regulation. Furthermore, the microarray gene 
set revealed a total of 12 cell cycle associated genes that were dysregulated in MEF2D 
deficient cardiomyocytes.  
The PI3K-AKT/PKB signaling pathway has a critical role in cell cycle progression 
and cell survival, and is activated in MEF2D deficient cardiomyocytes. Notably, we see an 
increase in cyclin D1, a downstream target of PI3K-AKT that promotes cell cycle 
progression. The upregulation of cell cycle genes occurs through PI3K-AKT activation, 
because blocking this pathway’s activation with the pharmacological inhibitor GDC-0941 
completely ablates or partially blocks the increase in cell cycle gene expression associated 
with MEF2D depletion. Furthermore, PTEN levels remain unaffected when PI3K/AKT 
activation is blocked. This is expected, because PTEN antagonizes PI3K mediated 
activation of AKT and its activity should not be affected by GDC-0941. One interesting 
implication of our findings is that MEF2D modulates PI3K-AKT activity through 
transcriptional activation of Pten. This newly uncovered role for MEF2D in PI3K-AKT 
regulation adds another layer of control to this already complex signaling pathway. 
Previous studies have demonstrated that PI3K-AKT negatively regulates MEF2D activity 
to allow for cell cycle progression in fibroblasts (Di Giorgio et al., 2013). We now take this 
pathway a step further and demonstrate that MEF2D blocks AKT activation through PTEN 
activation, and that its downregulation is necessary for AKT activation in cardiomyocytes. 
Furthermore, transcription factor binding enrichment analysis of the promoters for the six 
characterized positive cell cycle genes upregulated in MEF2D-deficient NRVMs revealed 
that fork head domains are enriched, implicating for head domain factors as transcriptional 
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regulators of these genes. Importantly, one subfamily, FOXO, is a direct AKT target. 
Although FOXO proteins traditionally function as transcriptional activators, one family 
member, FOXO3a, is known to function as a transcriptional repressor. We have shown that 
FOXO3a is enriched in the cytoplasm of MEF2D-depleted cardiomyocytes, suggesting that 
nuclear FOXO3a represses transcriptional activation of Ccne1, Ccne2, Mcm3, Mcm5, 
Mcm6, and Pcna in this context (Fig. 4.15).  
Given the significant increase in positive cell cycle gene and protein expression, 
we expected MEF2D deficient NRVMs to replicate. To our surprise, MEF2D depletion 
was not sufficient to drive cardiomyocytes to complete the cell cycle. It is possible that 
MEF2D dependent signaling pathways act in combination with other pathways to regulate 
cell division. The cell cycle is a tightly controlled process, and many regulatory networks 
exist to prevent aberrant activation.   
Taken together, the blunted cardiac remodeling observed in MEF2D knockouts and 
the newly uncovered role for MEF2D in the cell cycle suggest that MEF2D may be a key 
regulator in the pathology associated with cardiac disease. A better understanding of how 
MEF2D regulates cell cycle gene programs could lead to the discoveries of therapies that 
induce terminally differentiated cardiomyocytes in diseased hearts to re-enter the cell cycle 
and proliferate, and thus have a major impact on cardiovascular health. 
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Figure 4.1. Mef2d shRNA adenovirus efficiently knocks down MEF2D. A, quantitative 
RT analysis of endogenous Mef2 knockdown in neonatal rat ventricular myocytes 
(NRVMs) 72 hours post-transduction. The Mef2d shRNA adenovirus specifically knocks 
down Mef2d mRNA, without depleting Mef2a, Mef2b, or Mef2c mRNAs. B, Western blot 
analysis of endogenous MEF2D knockdown in NRVMs, and densitometry (C). shMef2d 
adenovirus efficiently knocks down MEF2D at both the transcript and protein level. The 
qRT data are means from seven independent experiments ±S.E. The Western blot analysis 
data are means from three independent experiments ±S.E. *, p < 0.05; ***, p <0.001. 
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Figure 4.2. Microarray validation in NRVMs. Quantitative RT-PCR analysis of cell 
cycle regulatory genes dysregulated in the Mef2d knockdown microarray. Mcm3, 
minichromosome maintenance complex component 3; Mcm5, minichromosome 
maintenance complex component 5; Mcm5, minichromosome maintenance complex 
component 6; Pcna, proliferating cell nuclear antigen; Ccne1, cyclin E1; Ccne2, cyclin E2. 
The primer sequences are listed under “Table 2.2” The data are means from six independent 
experiments ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001 
 
102 
 
 
 
FIGURE 4.3. Western blot analysis of cell cycle proteins in MEF2D deficient 
cardiomyocytes. A, Western blot analysis of the cell cycle promoting proteins cyclin D1, 
cyclin D3, CDK2, and PCNA show increased levels in MEF2D-deficient NRVMs. B, 
Western blot densitometry to quantify relative protein expression. The data are means from 
three independent experiments ± S.E. ***, p < 0.001 
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Figure 4.4. Examination of cell cycle inhibitors in MEF2D depleted NRVMs. 
Quantitative RT-PCR analysis of CIP/KIP and INK cell cycle inhibitors. Cdkn2a, cyclin-
dependent kinase inhibitor 2a (p16, Ink4a); Cdkn2c, cyclin-dependent kinase inhibitor 2c 
(p18, Ink4c); Cdkn2d, cyclin-dependent kinase inhibitor 2d (p19, Ink4d); Cdkn1a, cyclin-
dependent kinase inhibitor 1a (p21, Cip1); Cdkn1b, cyclin-dependent kinase inhibitor 1b 
(p27, Kip1); Cdkn1c, cyclin-dependent kinase inhibitor 1c (p57, Kip2). The primer 
sequences are listed under “List of Tables.” The data are means from six independent 
experiments ± S.E. **, p < 0.01; ***, p < 0.001 
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FIGURE 4.5. PTEN expression is down-regulated in MEF2D deficient NRVMs. A, 
Pten transcripts were down-regulated 2.5 fold in cardiomyocytes depleted of MEF2D. B, 
Western blot analysis confirms decreased levels of PTEN expression, with a 2.5 fold 
reduction of PTEN protein. C, Densitometry to quantify relative protein expression. The 
data are means from three or more independent experiments ± S.E. ***, p < 0.001 
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FIGURE 4.6. Identification of a highly conserved MEF2 binding site within the rat 
Pten promoter. A, The MEF2 binding site and flanking sequence located -4596 bases 
upstream of the putative Pten transcriptional start site is highly conserved among multiple 
species.  B, Schematic representation of the identified MEF2 binding site within the rat 
Pten promoter region. The core A/T sequence was mutated to disrupt binding in reporter 
and binding assays. The rat sequence was used for consistency with functional 
characterization of MEF2D in NRVMs. 
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FIGURE 4.7 MEF2D transcriptionally activates a Mef2 site contained within a Pten 
upstream regulatory region.  Luciferase analysis of the wild-type Pten promoter 
fragment containing an evolutionarily conserved MEF2 binding sites (-4596 Mef2). 
HEK293T cells were transfected with mouse MEF2D. The data are means from five 
independent experiments ± S.E. **, p < 0.01 
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FIGURE 4.8. MEF2D binds an evolutionarily conserved MEF2 site identified within 
the rat Pten regulatory region. Gel shift assay reveals binding of both in vitro translated 
and endogenous MEF2D to the wild-type (-4596 PTEN) but not mutant (–4596 MUT) 
Mef2 site identified within the rat Pten regulatory region. Incubation with MEF2D 
antibodies shift the MEF2 complex bound to the radiolabelled –4596 PTEN Mef2 
sequence. Binding of MEF2D to the –4596 PTEN Mef2 site is competed by the unlabeled 
wild-type, but not mutant sequence.  
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FIGURE 4.9. MEF2D depletion results in increased PI3K/AKT activation in NRVMs. 
A, Western blot analysis reveals an increase in AKT phosphorylation at the activating 
residues threonine 308 and serine 473 in MEF2D deficient cardiomyocytes. B, 
Accompanying densitometry to quantify Western blots. Samples were normalized to 
corresponding GAPDH. The data are means from three independent experiments ± S.E. *, 
p < 0.05; ***, p < 0.001 
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FIGURE 4.10. Examination of FOXO3a localization reveals cytoplasmic enrichment 
in MEF2D depleted NRVMs. A, FOXO3a protein is enriched in the nuclei of shlacZ 
transduced NRVMs, indicating that in these cells FOXO3a is transcriptionally active. 
Cardiomyocytes depleted of MEF2D display increased levels of cytoplasmic FOXO3a, 
suggesting FOXO3a inactivation in the absence of MEF2D. B, Closer magnification of 
labeled cells from panel A. Arrows point to FOXO3a protein localization.  
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FIGURE 4.11. PI3K inhibition blunts cell cycle gene dysregulation in MEF2D 
depleted NRVMs. PI3K/AKT inhibition by treatment with GDC-0941 blunts upregulation 
of positive cell cycle markers at the transcript level. Mcm3, minichromosome maintenance 
complex component 3; Mcm5, minichromosome maintenance complex component 5; 
Mcm5, minichromosome maintenance complex component 6; Pcna, proliferating cell 
nuclear antigen; Ccne1, cyclin E1; Ccne2, cyclin E2. The data are means from six 
independent experiments ± S.E. *, p < 0.05; ***, p < 0.001 
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FIGURE 4.12. PI3K inhibition does not affect Pten dysregulation in MEF2D-depleted 
NRVMs. PI3K/AKT inhibition by treatment with GDC-0941 does not have an effect on 
Pten transcript downregulation in MEF2D-depleted NRVMs. The data are means from six 
independent experiments ± S.E. ***, p < 0.001 
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FIGURE 4.13. MEF2D-deficient cardiomyocytes fail to complete the cell cycle. A, 
Cardiomyocytes were stained with Ki67, which is expressed in the active phases of the cell 
cycle. A muscle-specific marker, α-actinin, was used to distinguish cardiomyocytes from 
cardiac fibroblasts. Nuclei were stained with DAPI. B, Quantification of Ki67 stain. Ki67 
positive nuclei were quantified and divided by the total number of nuclei (DAPI) to obtain 
% Ki67 positive cells. Relative to the shlacZ control, MEF2D-depleted cardiomyocytes 
fail to express increased levels of Ki67 three days post transduction. C, The total number 
of cardiomyocytes (α-actinin positive cells) were quantified and averaged to obtain mean 
number of cardiomyocytes per condition. Arrows point to Ki67 positive nuclei. For 
quantification, at least 8 non-overlapping fields of view were analyzed per biological 
replicate. The data are means from eight independent experiments ± S.E. 
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FIGURE 4.14. Proliferation is absent in MEF2D-deficient cardiomyocytes. A, Three 
days post-transduction, EdU incorporation was measured to assay proliferation. There was 
no difference observed between MEF2D-depleted NRVMs and the shlacZ negative 
control. B, Quantification of EdU incorporation. EdU positive nuclei were quantified and 
divided by the total number of nuclei (DAPI) to obtain % EdU positive cells.  The data are 
means from three independent experiments ± S.E. 
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FIGURE 4.15.MEF2D regulates the cell cycle by modulating AKT signaling. In 
quiescent cardiomyocytes, MEF2D transcriptionally activates PTEN which antagonizes 
PI3K mediated AKT activation. In this context, AKT is not phosphorylated at the activating 
residues S473 and T308 and FOXO3a remains nuclear where it promotes cell cycle exit. 
MEF2D depletion results in downregulation of PTEN transcript and protein levels. 
Subsequently, PI3K mediates hyper-phosphorylation of AKT at the activating residues 
S473 and T308. Activated AKT directly phosphorylates FOXO3a, targeting it for 
cytoplasmic retention and inactivation. Ultimately this results in cell cycle activation.  
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TABLE 4.1. Analysis of molecular and cellular functions associated with MEF2D. 
Dysregulated genes were analyzed using Ingenuity Pathway Analysis software. The top 
five most significantly dysregulated molecular and cellular functions are given. These 
functions were analyzed for statistically significant association with MEF2D depletion, and 
all were found to be significant (p < 0.05). The number of genes dysregulated in each 
molecular and cellular function category is given. Each category contains genes both up- 
and downregulated, with both positive and negative functions in the associated pathway. 
Range of p-values for individual dysregulated genes in each category are indicated.   
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TABLE 4.2. Analysis of canonical pathways associated with MEF2D. Dysregulated 
genes were analyzed using Ingenuity Pathway Analysis software. The top five most 
significantly dysregulated canonical pathways are provided. These pathways were 
analyzed for statistically significant association with MEF2D depletion, and all were found 
to be significant (p < 0.05). Ratio values indicate the number of genes dysregulated in the 
MEF2D knockdown in relation to the accepted number of genes associated with each 
canonical pathway (ratio). 
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TABLE 4.3. KEGG pathway analysis of genes sensitive to the loss of MEF2D. 
Dysregulated genes were analyzed using Kyoto Encyclopedia of Genes and Genomes 
(KEGG). Of the four identified dysregulated canonical pathways, the cell cycle was the 
only one to have a statistically significant association with MEF2D depletion. (p < 0.05). 
The number of genes dysregulated in the indicated pathway is given. Percent values 
represent the number of dysregulated genes over the total number of genes associated with 
the indicated pathway.   
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TABLE 4.4. Cell cycle associated genes sensitive to the loss of MEF2D. Microarray data 
were sorted and analyzed for dysregulation of cell cycle associated genes. A ±1.5 fold 
cutoff revealed 279 dysregulated genes in cardiomyocytes. 4.3% (12) of the total number 
of dysregulated genes were involved in the cell cycle. Fold dysregulation is indicated along 
with gene, name, and protein symbol.  
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TABLE 4.5. Genomatix identified overrepresented TF binding sites. Binding site 
enrichment analysis was performed on cell cycle genes sensitive to the loss of MEF2D 
using the Genomatix software suite. Fourteen motifs were enriched with a calculated Z 
score greater than 2. The known binding factors and their relevant binding domains are 
included. Finally, a summary of the function of each of these binding factors is provided. 
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Module Description Z-Score Binding Domain Function 
GDNF-inducible zinc finger 
gene 1 
4.86 
BTB-POZ C2H2 
zinc fingers 
Negative regulation of 
transcription 
Iroquois homeobox 
transcription factors 
4.84 homeodomain 
Mesoderm 
development; Nervous 
system development 
Vertebrate TATA binding 
protein factor 
3.21  
DNA-dependent transcription, 
initiation 
RXR heterodimer binding 
sites 
2.98 
C4 zinc finger 
domain 
embryonic morphogenesis; 
apoptotic signaling pathway 
DM domain-containing  
transcription factors 
2.38 DM domain 
apoptotic process;  sex 
determination 
Bicoid-like homeodomain 
transcription factors 
2.29 homeodomain 
Wnt receptor signaling 
pathway; embryonic 
morphogenesis 
HOX - PBX complexes 2.27 
TALE class 
homeodomain 
adult locomotory behavior; 
anatomical structure 
morphogenesis; blood 
circulation;  
Fork head domain factors 2.24 fork head domain 
cardiac muscle cell 
proliferation; embryonic heart 
tube development; negative 
regulation of cell cycle 
Abdominal-B type 
homeodomain transcription 
factors 
2.07 homeodomain 
cell chemotaxis; embryonic 
morphogenesis; positive 
regulation of cell proliferation; 
skeletal muscle tissue 
development 
Ikaros zinc finger family 2.04 
C2H2 zinc finger 
domain 
mesoderm development 
Germ cell nuclear receptors 2.04 
C4 zinc finger 
domain 
cell proliferation 
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Chapter 5: E2F1-Mediated Cell Death in MEF2D-Deficient Cardiomyocytes 
5.1 Introduction 
E2F family members regulate a wide range of cellular processes, including 
pathways associated with cell proliferation and apoptosis (Polager and Ginsberg, 2008). 
As such, E2F activity is tightly regulated and aberrant activation can result in uncontrolled 
proliferation or cell death. Importantly, it is believed that E2F1, -2, and -3 promote 
apoptosis specifically in cells which initiate unscheduled DNA replication and abnormal 
cell cycle re-entry. Several studies demonstrate that certain cell types will induce apoptosis 
in response to cell cycle re-entry. Particularly, when neurons initiate proliferation they fail 
to complete the cell cycle and ultimately undergo apoptosis (Herrup and Yang, 2007). We 
observe a similar state in cardiomyocytes that have been depleted of MEF2D. MEF2D-
deficient cardiomyocytes induces AKT activation which results in an up-regulation of a 
wide range of positive cell cycle markers such as cyclins, CDKs, and E2F1, -2, and -3. 
However, these cells fail to complete the cell cycle and begin to die after five days of 
MEF2D depletion. Inhibition of PI3K-AKT/PKB restores cardiomyocyte viability induced 
by MEF2D deficiency, suggesting that the observed cell death is directly correlated with 
cell cycle activation. We propose a model by which MEF2D depletion results in aberrant 
cell cycle activation in cardiomyocytes. This unscheduled induction of the cell cycle is 
sensed by E2F, which then promotes apoptosis to prevent uncontrolled proliferation 
thereby avoiding tumorigenesis.  
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5.2 MEF2D is cardioprotective and its loss results in reduced cell viability 
MEF2D promotes survival in neurons and its loss results in neuronal cell death 
(Salma and McDermott, 2012). We sought to determine whether MEF2D acts in a similar 
protective manner in cardiomyocytes. First, NRVMs were depleted of MEF2D for three, 
five, or seven days and assayed for cell viability. CellTiter-Blue® cell viability assays 
demonstrated that after three days of MEF2D depletion, there was no appreciable loss of 
cardiomyocyte viability (Fig.5.1A). By day five, MEF2D-depleted cardiomyocytes 
showed a slight reduction in viability (Fig.5.1B). Finally, after seven days of MEF2D 
depletion, nearly all cardiomyocytes were no longer viable as compared to the negative 
control (Fig.5.1C). These data suggest that MEF2D depletion decreases cardiomyocyte 
survival. 
Given the decreased viability upon knockdown of MEF2D, we asked whether 
overexpressing MEF2D could slow down or rescue cardiomyocyte cell death in culture. In 
a complementary set of experiments, MEF2D was overexpressed (OE) in cardiomyocytes 
for three, five, or seven days. The MEF2D overexpression construct resulted in an almost 
6-fold increase in MEF2D levels in NRVMs (Fig. 5.2A, B). NRVMs have a lifespan in 
culture of approximately 10 days, so we expected the negative control to show a reduction 
in viability over time. There was no appreciable difference in viability between MEF2D 
OE cells and the negative control three days after transduction (Fig. 5.1D). However, we 
noted a significant increase in viability in MEF2D OE cells five and seven days post-
transduction (Fig. 5.1E, F). Ectopic MEF2D expression prevented the typical cell death 
observed in this culture model, prolonging primary cardiomyocyte lifespan in culture. 
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Taken together, these results demonstrate that MEF2D is cardioprotective, and that its loss 
leads to a marked reduction in cardiomyocyte viability. 
Next, we sought to understand the mechanism by which MEF2D depletion results 
in reduced viability. Cell death is a complex process that can occur via several mechanisms 
such as necrosis, phagocytosis, and apoptosis. Our model proposes that E2F1-3 is 
responsible for inducing apoptosis in response to aberrant cell cycle induction. One 
mechanism by which E2F1-3 promote apoptosis is by inducing expression of the initiator 
caspases (caspase-8 and -9) and effector caspases (caspase-3 and 7). To determine whether 
apoptosis was being induced in MEF2D-deficient cells, we performed a caspase-3 activity 
assay three, five, and seven days post transduction. Ac-DEVD-AMC is a fluorogenic 
substrate that is cleaved by active caspase-3, giving a fluorescent read-out of caspase-3 
activity in the cell. In line with CellTiter-Blue® cell viability assay results, there was no 
significant change in caspase-3 activity three days post-transduction (Fig. 5.3A). However, 
after five and seven days of MEF2D depletion there was a significant increase in caspase 
activity (Fig. 5.3B, C), suggesting that cardiomyocyte cell death was occurring through 
apoptosis. Conversely, MEF2D overexpression did not modulate caspase-3 activity in 
cardiomyocytes after three or five days in culture (Fig. 5.3D, E). However, there was a 
significant decrease in caspase-3 activity when MEF2D was overexpressed in 
cardiomyocytes for seven days (Fig. 5.3F).   
In a complementary set of experiments we performed terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) to measure apoptotic cell death. Dying cells 
were clearly visible under a phase contrast microscope after five days of MEF2D depletion 
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(Fig. 5.4). Importantly, cells transduced with the negative control display a healthy 
morphology with a minimal number of rounded light refractive cells at this time point, and 
are representative of normal, undying cells. Therefore, we chose the day five time-point 
for cell death assays. We used immunocytochemistry to examine cardiomyocyte gross 
morphology and number, and observed an approximately two-fold decrease in 
cardiomyocyte numbers after five days of MEF2D depletion (Fig. 5.5A, B). TUNEL assay 
revealed an approximately 3.5-fold increase in apoptotic cell death in MEF2D-depleted 
cardiomyocytes (Fig. 5.5C, D). It is important to note that we were unable to perform 
TUNEL at later time points due to the limited lifespan of primary cardiomyocytes in 
culture.  
 To further molecularly dissect the role of apoptosis in cardiomyocyte cell death 
induced by MEF2D depletion, we examined transcript levels of E2F1, -2, and -3, and two 
of their pro-apoptotic targets Apaf1 and Casp8. Unsurprisingly, MEF2D-deficient 
cardiomyocytes demonstrated a 1.8-, 4-, and 2.6-fold increase in E2f1, -2, and -3 mRNA 
levels, respectively (Fig. 5.6). Furthermore, APAF1 and Caspase-8 transcripts were 
upregulated 1.7- and 3-fold in MEF2D-deficient cardiomyocytes, respectively (Fig. 5.7). 
Examination of Xiap, an inhibitor of apoptosis, corroborated our findings with a 2.5-fold 
reduction of mRNA expression of this pro-survival factor in MEF2D-deficient 
cardiomyocytes (Fig. 5.8).  
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5.3 Inhibition of cell cycle re-entry blocks apoptosis in MEF2D-deficient NRVMs 
It stands to reason that if aberrant cell-cycle re-entry is causing E2F-mediated 
apoptosis in the absence of MEF2D, then blocking cell cycle re-entry should rescue the 
observed cell death phenotype. MEF2D-deficient cardiomyocytes were again treated with 
the pharmacological PI3K inhibitor GDC-0941, which we previously demonstrated blunts 
activation of cell cycle proteins. TUNEL was performed on MEF2D-deficient cells treated 
with GDC-0941 for five days. Inhibition of PI3K completely ablated the 3.5-fold increase 
in cell death observed in the absence of MEF2D alone (Fig. 5.9A, B). Moreover, treatment 
with GDC-0941 blocked the upregulation of expression of E2f1-3 (Fig. 5.10), as well as 
Apaf1 and Casp8 (Fig. 5.11) observed in MEF2D depleted cardiomyocyte. Moreover, 
inhibition of PI3K/AKT activation blunted the significant decrease in Xiap transcript levels 
in response to MEF2D depletion (Fig. 5.12).  
5.4 Discussion 
MEF2D has an established role as a pro-survival factor in neurons and has been 
implicated in cell cycle regulation in a variety of cell types. We have demonstrated that 
MEF2D shares this pro-survival functionality in cardiomyocytes, and that depletion of this 
factor results in cell death. The E2F family of transcription factors have critical roles in 
both proliferation and cell death, and the activating E2F1, -2, and -3 are significantly 
upregulated in the absence of MEF2D. Our results demonstrate that MEF2D depletion 
results in aberrant cell cycle activation, ultimately resulting in reduced viability and cell 
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death. These findings suggest that deregulated MEF2D is a contributing factor in the 
pathology associated with cardiac disease (Fig. 5.13).   
The E2F family of transcription factors are critical regulators of pathways 
associated with cell proliferation, differentiation, development, and cell death. It is 
paradoxical how activating E2Fs are able to regulate seemingly opposing pathways in the 
cell, and there is much debate on the mechanisms E2Fs employ to decide whether a cell 
should live or die. One proposed model is that the activating E2Fs are post-translationally 
modified, altering E2F activity. Yet another explanation is that the mechanisms employed 
by these E2Fs to induce cell proliferation or apoptosis are dependent on co-factors and 
interacting proteins. Nevertheless, increased levels of E2F1-3 activity are associated with 
both increased cell proliferation and cell death, making these E2Fs both oncogenes and 
tumor suppressors in a context dependent manner (Polager and Ginsberg, 2008). Several 
studies demonstrate that ectopic expression of E2F1 induces apoptosis both in vitro and in 
vivo (Stanelle and Putzer, 2006). Furthermore, E2F1 appears to only induce apoptosis when 
its activity is deregulated, possibly as a failsafe mechanism to prevent tumorigenesis 
(Polager and Ginsberg, 2008). This type of mechanism is important in cell types which 
should remain in a terminally differentiated state for proper function, such as in the 
mammalian heart.  
Cardiomyocytes in the newborn mammalian heart have the ability to re-enter the 
cell cycle in response to injury, thereby affording the neonatal mammalian heart the 
capacity to regenerate (Drenckhahn et al., 2008; Porrello et al., 2011). This regenerative 
potential is lost within a week after birth at which time cardiomyocytes permanently exit 
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the cell cycle (Pasumarthi and Field, 2002; Rumyantsev, 1977), thus rendering the adult 
mammalian heart largely incapable of repairing itself in response to injury and stress. 
Interestingly, depleting cardiomyocytes of MEF2D induces AKT activation which results 
in an upregulation of positive cell cycle markers such as cyclins, CDKs, and E2F1-3. 
However, these cardiac cells fail to progress through the cell cycle and ultimately die. A 
similar scenario occurs in the brains of patients who suffer from neurodegenerative 
diseases. In an attempt to replenish damaged neurons, populations of neurons will re-enter 
the cell cycle but these neurons fail to complete the cell cycle and instead undergo cell 
death. However, contrary to our observations in cardiomyocytes, the studies performed in 
neurons show partial DNA replication (Herrup and Yang, 2007). Interestingly, MEF2D is 
implicated as a negative regulator of proliferation in a variety of cell types (Di Giorgio et 
al., 2013), and the loss of MEF2D promotes apoptosis in brain cells (Kim et al., 2011; 
Salma and McDermott, 2012), possibly due to aberrant activation of the cell cycle. It is 
plausible that MEF2D has a similar role in cardiomyocytes, where its role is to maintain 
normal healthy cells in a quiescent state. It is likely that the abnormal induction of the cell 
cycle in MEF2D-depleted cardiomyocytes results in E2F1-mediated cell death.  
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 FIGURE 5.1. Analysis of cardiomyocyte viability in response to MEF2D levels.  
MEF2D depleted NRVMs were cultured for three, five, and seven days and viability was 
measured with CellTiter Blue cell viability assay. A, MEF2D depleted NRVMs showed no 
significant change in viability three days post-transduction. Five (B) and seven days (C) of 
MEF2D depletion resulted in decreased cardiomyocyte viability. Conversely, 
overexpression of MEF2D for three days had no effect on viability (D). MEf2D 
overexpresion for five (E) and seven days (F) resulted in increased cell viability of cultured 
cardiomyocytes. The data are means from three independent experiments ± S.E. *, p < 
0.05; **, p < 0.01; ***, p < 0.001                 
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 FIGURE 5.2. MEF2D overexpression in NRVMs. A, Western blot analyses of C2C12 
cells transduced with MEF2D adenovirus confirms an increase in MEF2D protein levels, 
relative to the β-gal control. OE, overexpression. B, quantification of MEF2D Western blot 
analysis the experiment shown in A.  
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FIGURE 5.3. Caspase-3 activity assay in NRVMs. Ac-DEVD-AMC is a caspase-3 
substrate which emits fluotrescence when cleaved by activated caspase-3. Cells were 
incubated with Ac-DEVD-AMC and caspase-3 activity was measured in response to 
MEF2D depletion or overexpresison in cardiomyocytes. A, There was no difference in 
cardiomyocyte caspase-3 activity after three days of MEF2D depletion. MEF2D deficient 
NRVMs display increased levels of caspase-3 activity five (B) and seven days post-
transduction (C). MEF2D overexpression had no effect on cardiomyocyte viability three 
(D) and five days post-transduction (E). However, MEF2D overexpression resulted in 
decreased caspase-3 activity in cardiomyocytes after seven days in culture (F). The data 
are means from three independent experiments ± S.E. *, p < 0.05; **, p < 0.01 
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FIGURE 5.4. MEF2D depletion results in cardiomyocyte cell death. Phase contrast 
image NRVMs five days post-transduction. MEF2D-depleted cells are rounded and light 
refractive, when compared to the shlacZ control. 
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FIGURE 5.5. MEF2D deficient NRVMs undergo apoptosis. A, Five days post-
transduction, cardiomyocytes were stained with α-actinin, a muscle specific marker, to 
distinguish NRVMs from cardiac fibroblasts.  B, MEF2D depletion resulted in a 2-fold 
decrease in cardiomyocyte cell number. C, MEF2D deficient cardiomyocytes have 3.5-fold 
more TUNEL positive cells than the control, indicating apoptosis is occuring in these cells. 
D, Quantification of TUNEL assay results. The data are means of three or more 
independent experiments.  ± S.E. *, p < 0.05, **, p < 0.01  
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FUGURE 5.6. E2F transcripts are upregulated in MEF2D deficient cardiomyocytes. 
Quantitative RT-PCR analysis of the mRNA of activating E2Fs, E2f1, E2f2, and E2f3 
reveal that MEF2D deficiency results in their increased expression. Curiously, E2f4, a 
repressive E2F, was also significantly upregulated in the absense of MEF2D. E2f5 levels 
were unaffected. The data are means from six independent experiments ± S.E. *, p < 0.05; 
**, p < 0.01. 
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FIGURE 5.7. Increased levels of E2F target genes in the absence of MEF2D. 
Quantitative RT-PCR analysis of two pro-apoptotic transcriptional targets of E2F. Apaf1 
and Casp8 transcripts are significantly increased in MEF2D depleted NRVMs. Apaf1, 
apoptotic peptidase activating factor 1; Casp8, caspase-8. The data are means from six 
independent experiments ± S.E. *, p < 0.05 
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FIGURE 5.8. Anti-apoptotic factor Xiap mRNA is downregulated in MEF2D depleted 
NRVMs. Xiap, X-linked inhibitor of apoptosis. The data are means from six independent 
experiments ± S.E. **, p < 0.01 
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FIGURE 5.9. PI3K/AKT inhibition rescues apoptotic cell death associated with 
MEF2D depletion. A, PI3K/AKT activation was inhibited in MEF2D-deficient 
cardiomyocytes by addition of GDC-0941. Treatment with GDC-0941 abolished the cell 
death phenotype observed in MEF2D-deficient NRVMs five days post-transduction. B, 
Quantification of TUNEL assay results. The data are means from five independent 
experiments ± S.E.  
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FUGURE 5.10. PI3K/AKT inhibition abolishes E2F transcript upregulation in 
MEF2D deficient cardiomyocytes. Quantitative RT-PCR analysis of mRNA encoding 
activating and inhibitory E2Fs. Expression of E2f1 was significantly was significantly 
reduced in MEF2D deficient NRVMs treated with GDC-0941. The data are means from 
six independent experiments ± S.E. ***, p < 0.001. 
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FIGURE 5.11. E2F target genes are unaffected in MEF2D deficient cardiomyocytes 
treated with GDC-0941. Quantitative RT-PCR analysis of two pro-apoptotic genes that 
are transcriptional targets of E2F. The significant increase of Apaf1 and Casp8 transcripts 
in MEF2D depleted NRVMs is abolished when PI3K/AKT activation is inhibited by 
addition of GDC-0941. Apaf1, apoptotic peptidase activating factor 1; Casp8, caspase-8. 
The data are means from six independent experiments ± S.E.  
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FIGURE 5.12. mRNA levels of anti-apoptotic factor Xiap are not significantly affected 
when PI3K/AKT is inhibited in MEF2D depleted NRVMs. The significant increase of 
Xiap transcripts in MEF2D depleted NRVMs is abolished when PI3K/AKT activation is 
inhibited by addition of GDC-0941.  Xiap, X-linked inhibitor of apoptosis. The data are 
means from six independent experiments ± S.E.  
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FIGURE 5.13. MEF2D depletion results in aberant cell cycle re-entry and 
cardiomyocyte cell death. Post-natal cardiomyocytes are terminally differentiated, and 
are unable to re-enter the cell cycle. MEF2D depletion results in a downregulation of the 
PI3K antagonist and AKT negative regulator, PTEN. This decrease in PTEN allows for 
PI3K mediated hyperphosphorylation and activation of AKT, which then directly 
phosphorylates FOXO3a to inactivate it. Cytoplasmic FOXO3a is unable to bind upstream 
regulatory regions of positive cell cycle genes to repress their transcriptional activation. 
This de-repression results in an upregulation of Mcm3, Mcm5, Mcm6, Pcna, Ccne1, and 
Ccne2, and aberant cell cycle re-entry. E2F transcription factors sense unprogrammed cell 
cycle activation, and mediate cardiomyocyte apoptosis by transcriptionally activating pro-
apoptotic genes Apaf1 and Casp8.  
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Chapter 6: Discussion and Future Perspectives 
6.1 Discussion 
The MEF2 family of transcription factors has well-established roles in muscle 
development, differentiation, and regeneration. The molecular mechanisms by which 
MEF2 controls gene expression and how its activity is regulated by signaling pathways in 
muscle have been intensely investigated. However, until recently, potential differences in 
MEF2 isoforms and individual transcriptional functions had not been thoroughly 
investigated. Isoform-specific knockdown of the mammalian MEF2 proteins in a well-
defined muscle context followed by genome-wide expression profiling has allowed us to 
carefully examine the requirement of each MEF2 isoform and its downstream pathways in 
striated muscle.  
Using the C2C12 cell culture model of skeletal muscle differentiation we were able 
to demonstrate that MEF2A is required for C2C12 differentiation, and that the remaining 
MEF2 proteins, MEF2B, C, and D, were dispensable for this process. However, although 
depletion of MEF2B, C, or D either individually or in combination did not cause 
differentiation defects, deficiency of these individual MEF2 isoforms resulted in 
significant gene dysregulation. Genome-wide expression profiling revealed that the 
number of genes sensitive to the loss of MEF2 covered a broad spectrum of cellular 
processes. Furthermore, our findings reveal isoform-specific differences in the regulation 
of genes by the mammalian MEF2 transcription factors in C2C12 differentiation. In silico 
analysis of promoter regions for genes differentially sensitive to the loss of the four 
mammalian MEF2 isoforms suggest that MEF2-dependent transcriptional regulation is 
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modulated by co-factor interactions and not through differences in the MEF2 consensus 
sequence.  
Whereas all four MEF2 family members are expressed in adult skeletal muscle, 
MEF2A and MEF2D are the major isoforms expressed in the post-natal heart. The 
functional role of MEF2A in cardiomyocytes has previously been characterized (Ewen et 
al., 2011). Presently, we have presented genome-wide expression analysis demonstrating 
a role for MEF2D in cardiomyocyte cell cycle regulation. We have demonstrated that 
MEF2D modulates PI3K/AKT activity in cardiomyocytes through transcriptional 
regulation of the tumor suppressor Pten. MEF2D depletion results in PI3K/AKT activation 
resulting in an up-regulation of a subset of positive cell cycle regulators, and suppression 
of the FOXO3a transcription factor, which negatively modulates cell cycle activation.  This 
aberrant activation of the cell cycle in response to MEF2D depletion ultimately results in 
cardiomyocyte cell death likely mediated through the activation of E2F transcription 
factors.  
Genome-wide expression analysis of genes sensitive to the loss of MEF2 definitely 
demonstrate that MEF2 family members regulate distinct gene programs required for 
proper skeletal and cardiac muscle function. These findings will be useful in future studies 
aimed at developing therapies to treat muscular dystrophies and cardiovascular disease. 
Exploiting gene programs regulated by MEF2 in muscle provides us with a new avenue to 
induce muscle regeneration and proliferation.  
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6.2 Future Perspectives 
6.2.1 MEF2 transcription factors regulate distinct gene programs in mammalian 
skeletal muscle differentiation 
The data presented in Chapter 3 of this thesis demonstrate that MEF2 family 
members have distinct roles in mammalian skeletal muscle differentiation. We show that 
MEF2A is absolutely required for differentiation of C2C12 myoblasts, and that the other 
family members MEF2B, -C, and –D are dispensable in this process. However, this body 
of work has left a number of unanswered questions, and future work will continue to dissect 
the precise roles of each MEF2 family member in this process.  
Our work demonstrates that a distinct cohort of genes are preferentially sensitive to 
the loss of individual MEF2 family members, however whether MEF2 is responsible for 
direct transcriptional regulation of these genes has yet to be determined. Initially, the 
promoters of genes sensitive to the loss of MEF2 would have to be analyzed for putative 
MEF2 binding sites. It would be interesting to perform ChIP assays on the upstream 
regulatory regions of dysregulated genes identified as having MEF2 binding sites. This 
type of analysis would allow us to identify potential direct MEF2 targets and gene-specific 
MEF2 dimers among the dysregulated gene set. At this time highly-specific MEF2 protein 
isoform antibodies are not available. Therefore, these experiments would require the 
generation of antibodies to specific MEF2 isoforms. Furthermore, the promoters of the 
genes containing putative MEF2 binding sites could be used to generate Luciferase reporter 
constructs, which would allow us to determine whether MEF2 proteins transcriptionally 
regulate these target genes in the context of the cell in an isoform-specific manner. The 
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results from these experiments would help use expand on the list of known MEF2 target 
genes and the cellular pathways in which they are involved.  
C2C12 cells are proliferating myoblasts committed to skeletal muscle 
differentiation. As a result, these cells are widely used as an in vitro model of muscle 
differentiation. C2C12 cells will initiate the differentiation program upon serum 
withdrawal, and most cells will exit the cell cycle and fuse to form myotubes by day three 
of serum deprivation. These myoblasts were initially isolated from injured murine thigh 
muscle, and more closely recapitulate a muscle regeneration gene program rather than 
developmental myogenesis (Snyder et al., 2013). It would be interesting to determine 
whether our comparative analysis of gene programs regulated by individual MEF2 family 
members is recapitulated in developmental myogenesis. This type of comparison would be 
relatively straightforward, as loss-of-function mouse models exist for each MEF2 family 
member. Skeletal muscle derived RNA would be obtained from developing embryos at the 
onset of MEF2 expression and induction of myogenesis. A comparative microarray 
analysis could then be performed and compared to our C2C12 results. However, obtaining 
sufficient RNA from embryonic muscle is technically challenging, and a more feasible 
approach would be to harvest muscle from later fetal stages or neonatal myoblasts. This 
type of analysis would help us understand how much overlap there is between 
developmental and regenerative gene programs. Understanding the extent to which these 
processes overlap provide the field with greater knowledge on pathways necessary for 
proper muscle formation. In the future, developmental gene programs can be triggered to 
promote a more complete muscle and possibly even limb regeneration.  
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One additional experiment that should be performed is depleting primary myoblasts 
of each MEF2 protein and determining the effects on differentiation. These results should 
mirror our findings in C2C12 myoblasts. However, there remains the possibility that 
primary myoblasts will produce a different result. C2C12 myoblasts were isolated from 
injured muscle, and may not be completely representative of transcriptional gene programs 
turned on in healthy muscle. Nevertheless, these additional experiments will add depth to 
the work presented in this thesis, allowing us to better understand the role each mammalian 
MEF2 protein has in skeletal muscle development and differentiation.  
6.2.2 MEF2D sustains cardiomyocyte cell cycle arrest through transcriptional 
regulation of PTEN 
We have demonstrated that depleting cardiomyocytes of MEF2D results in cell 
cycle perturbations. MEF2D depleted NRVMs display increased levels of genes which 
promote DNA replication and cell cycle progression. Notably, MEF2D depletion results in 
a two-fold reduction of the tumor suppresser PTEN. We hypothesize that MEF2D 
maintains cardiomyocytes in a terminally differentiated by transcriptionally activating 
Pten, an important negative regulator of the PI3K-AKT/PKB pathway which when left 
unchecked results in tumorigenesis. Upon MEF2D depletion, PTEN levels decrease 
allowing for an increase in AKT phosphorylation and activation, resulting in activation of 
the cell cycle in MEF2D deficient cardiomyocytes. Subsequently, we see an upregulation 
of positive cell cycle markers and cytoplasmic localization of FOXO3a. These findings 
suggest that MEF2D depletion results in cell-cycle re-entry in cardiomyocytes, however 
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much remains to be learned about the role of MEF2D in cardiomyocyte cell cycle control 
before these findings can be translated into therapies aimed at treating cardiovascular 
disease. 
The most glaring question we are left with is why MEF2D depleted NRVMs do not 
display an increase in DNA synthesis, despite the up-regulation of genes and proteins 
involved in replication. One important experiment to perform would be EdU incorporation 
assays at various time-points after MEF2D knockdown. We see an up-regulation of 
replication genes and protein after three days of MEF2D depletion. Perhaps performing an 
EdU incorporation assay 6-12 hours after induction of the cell cycle would reveal DNA 
synthesis.  
 A closer examination of phosphorylation states of FOXO transcription factors is 
necessary for the completion of this study. FOXO proteins are repressed when 
phosphorylated by active AKT. MEF2D depleted NRVMs have increased AKT activity 
levels, so it stands to reason that we should see an increased level of FOXO 
phosphorylation. In this study we focused exclusively on FOXO3a, and determined that 
MEF2D depleted cardiomyocytes had increased levels of cytoplasmic (inactivated) 
FOXO3a. It would be interesting to see if this is also the case with FOXO1, the other FOXO 
family member directly targeted by AKT. Like FOXO3a, FOXO1 is expressed in the 
developing heart and at low levels in the adult heart (Evans-Anderson et al., 2008). 
Moreover, increased levels of FOXO1 have been observed in human heart failure 
(Hannenhalli et al., 2006). Because both FOXO1 and FOXO3a have established roles in 
cardiac development and are implicated in cardiac dysfunction (Evans-Anderson et al., 
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2008), understanding signaling pathways regulating their transcriptional activity is 
important. In this study, we did not note an appreciable change in transcript levels of p21 
and p27, two FOXO targets which repress the cell cycle. It would be interesting to look at 
p21 and p27 phosphorylation states, as post-translational modification of these negative 
cell cycle regulators is known to affect their repressive activity.  
 Finally, the effects of MEF2D depletion in cardiomyocytes should be investigated 
in vivo. Previous studies in the MEF2D knockout mouse demonstrated a role for MEF2D 
in cardiac remodeling in response to stress, however gene programs dysregulated in 
MEF2D deficient hearts were not explored (Kim et al., 2008). Given the newly uncovered 
role for MEF2D in cardiomyocyte cell cycle control and survival presented in this thesis, 
one important experiment to perform on MEF2D knockout mice would be determining 
how MEF2D depletion affects regeneration in the injured heart.  We know that MEF2D 
depletion blunts the pathology associated with cardiac injury, however the mechanism by 
which this occurs is currently unknown (Kim et al., 2008). It is possible that MEF2D 
depletion is resulting in cardiomyocyte repair and amelioration of the pathology associated 
with cardiac tissue damage.  
 These additional experiments would serve to better define the mechanism by which 
MEF2D regulates the cell cycle in cardiomyocytes. Once fully dissected, this body of work 
will contribute invaluable knowledge about post-natal cardiomyocyte replication to the 
cardiac field. Several studies have developed strategies to potentially treat heart damage 
by reprogramming resident cardiac fibroblasts and other cell types into cardiomyocytes in 
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an attempt to circumvent the lack of cardiac regenerative capacity (Ieda et al., 2010; Kong 
et al., 2010). However, these methods are invasive and have not been approved for use in 
patients. A more efficient method of therapy would be to de-differentiate cardiomyocytes 
to induce cell cycle re-entry and proliferation, thereby allowing resident cardiac cells to 
repopulate the heart with healthy cells. Understanding the mechanisms governing 
cardiomyocyte cell cycle control is the first step in developing therapies to regenerate 
damaged cardiac muscle.  
6.2.3 E2F1-mediated cell death in MEF2D-deficient cardiomyocytes  
We have demonstrated that MEF2D is cardioprotective, and depletion of this factor results 
in cell death. MEF2D deficient cardiac myocytes initiate the cell cycle but fail to complete 
the process. In this scenario, it is possible that E2F recognizes cell cycle activation in 
cardiomyocytes as an aberrant event. In an attempt to stop deregulated proliferation, E2F 
activates the pro-apoptotic genes Apaf1, Casp3, and Casp8 which ultimately results in 
cardiomyocyte death in a p53 independent manner. 
Much remains to be learned about how E2F determines whether a cell should 
proceed with proliferation or induce apoptosis. Several of the positive cell cycle genes up-
regulated in MEF2D depleted NRVMs are E2F transcriptional targets. It is unclear to us 
whether E2F is responsible for this increase in positive cell cycle markers, and this area 
warrants further investigation. However, it would be paradoxical for E2F to activate the 
cell cycle and apoptosis simultaneously. In order to determined which aspect of this 
phenotype E2F is modulating, the activating E2F family members E2F1-3 should be 
knocked down individually and in combination in MEF2D depleted NRVMs. Two 
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outcomes are possible. In the first scenario, E2F inhibition would block cell cycle 
activation, indicating that E2F is mediating cell cycle re-entry in this context. In a second 
scenario, E2F depletion in a MEF2D deficient background may result in cell-cycle 
activation without the associated cell death, perhaps allowing cell cycle completion to 
occur.  
E2F family members mediate apoptosis through p53 dependent and p53 
independent pathways. We have presented data suggesting that E2F is activating a p53 
independent pathway to induce apoptosis in MEF2D depleted NRVMs. However it is 
uncertain whether p53 dependent mechanisms are contributing to the observed cell death. 
Further characterization of these apoptotic pathways is necessary to gain a better 
understanding of how E2F promotes cardiomyocyte cell death. This research will help us 
to exploit this pathway in therapies aimed at preventing cardiomyocyte loss associated with 
cardiovascular disease.  
The E2F family of transcription factors are critical in mediating cell proliferation. 
Paradoxically, in addition to promoting proliferation E2F1, -2, and -3 can also promote 
apoptosis. It is hypothesized that E2F mediated cell death is a protective response initiated 
by the cell to prevent tumor growth when unscheduled proliferation is activated. A better 
understanding of how MEF2D in combination with E2F regulate cell cycle gene programs 
could lead to the discoveries of therapies that induce terminally differentiated 
cardiomyocytes in diseased hearts to re-enter the cell cycle and proliferate, and thus have 
a major impact on cardiovascular health. 
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